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ABSTRACT 
 
 
Solubility behavior is one of the most challenging aspects for drug 
commercialization and often the main reason of drug that do not reach to its full potential. 
Now nearly 60% new chemical entities possess solubility problems, whereas practically 
no drug products with less than 10 μg/ml solubility in 70’s or 80’s. There is an ever 
increasing need to develop new formulation techniques and exicipients with novel 
mechanisms of action. Various techniques have been applied to enhance the drug 
solubility such as co-solvents, particle size reduction, lipid based drug delivery systems, 
nanosuspension, use of surfactants, salt formation, cyclodextrin complexes and solid 
dispersion etc.  
 
Chapter 1 is an introduction into biopharmaceutics classification system (BCS) 
and novel drug solubilization techniques. It provides a brief history of the BCS and its 
application in drug development. It also looks into the recent poorly water soluble drugs 
approved by the Food and Drug Administration and the formulation techniques that these 
drugs used.  
 
Chapter 2 is a brief history of solid dispersion, including its theoretical basis, 
preparation methods, and characterization and quality control tools. Several drug 
products using solid dispersion technique are also reviewed. This chapter is intended to 
combine recent literature on solid dispersion technology for solubility enhancement with 
various preparation methods, evaluation parameters and commonly used polymer 
carriers.  
 
Chapter 3 explores the applicabability of a cold water soluble modified starch, 
octenyl succinic anhydrate starch (OSA starch) as solid dispersion carrier to increase the 
aqueous solubility and dissolution rate of poorly water soluble drugs. When using OSA 
starch in solid dispersions via spray drying techniques, the hypothesis is that drug is 
dissolved in the starch solution, when water evaporate via spray drying, drug will be 
solidified together with starch and mostly the drug is in amorphous form because the 
rapid spray drying process (seconds) prevents drug crystallization. In this system, the 
starch is homogenously distributed in the matrix and thus prevents drug crystalline 
growth as a characteristic of the polymer. When drug is dispersed in starch solution, the 
starch will encapsulate drug particles to complete the microencapsulation process and 
micro-scale drug particles will be retained in the starch matrix. These properties will be 
helpful in enhancing drug solubility and dissolution rate. 
 
Chapter 4 explores a solid dispersion of furosemide and  
sulfobutylether-β-cyclodextrin which was another derivative excipient of starch. Solid 
dispersion preparation method and mechanism are also discussed. The work serves as a 
positive control for OSA starch solid dispersion. Comparison and contrasting the two 
solid dispersions assist in the interpretation of OSA starch solid dispersions. 
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CHAPTER 1.    BACKGROUND 
 
 
1.1 Biopharmaceutics Classification System (BCS)  
 
The Biopharmaceutics classification system (BCS) was introduced in 1995 by 
Gordon L. Amidon et al. to correlate the drug in vitro dissolution performance to in vivo 
bioavailability (IVIVC) [1]. Two primary parameters: solubility and permeability were 
utilized as the basis for this drug classification system. In the system, four categories are 
applied to drugs: class I, high solubility, high permeability; class II low solubility, high 
permeability; class III, high solubility, low permeability; class IV, low solubility, low 
permeability.  
 
In the system, the definition of high solubility is that the highest dose is soluble in 
250 ml or less of water over a pH range of 1–8 at 37 °C. Permeability is defined as 
effective human jejunal wall permeability of a drug; the unit is 10-4 cm per second. High 
permeability means no less than 90% extent of absorption and at the same time, these 
drugs are basically stable in GI tract [2]. It is generally accepted that drug dissolution is 
the prerequisite for drug absorption for any orally given dosage form based on human GI 
tract physiological condition. For orally given drugs, passive transcellular diffusion is the 
major mechanism for drug absorption [3].The mass of drug across the mucosal 
membrane of intestine is the upper limit amount that ready to enter system circulation [4]. 
 
 
1.1.1 Relation between Do, Dn, An, and dissolution 
 
Besides solubility and permeability, three dimensionless parameters are also 
introduced to describe the relationship between dose, dissolution, drug solubility and 
drug permeability [4]. They are absorption number (An); dissolution number (Dn); and 
dose number (Do).  Several equations are derived to describe the relation between those 
variables. For absorption number (An), it equals the permeability of drug divided gut 
radius and then times residence time or transit time of drug, see Equation 1-1. 
 
Absorption number (An) = (Peff/R) • <Tsi> (Eq. 1-1) 
 
Where Peff is permeability, R is the gut radius and <Tsi> is the residence time of 
the drug within the intestine. Dissolution behavior is complex, for dissolution number 
(Dn), five variables are included in its equation: drug diffusivity, particle radius, 
solubility, density, and residence time, see Equation 1-2. 
 
Dissolution number (Dn) = (3D/r2) • (Cs/) • <Tsi > (Eq. 1-2) 
 
 In this equation, D is the diffusivity of the dissolved drug, r is the initial radius of 
the drug particle, Cs is the drug solubility, and  is the density of the dissolved drug; <Tsi 
> is the same as in Equation 1-1. The concentration gradient of drug in gut is the original 
driving force for its diffusion which decided its diffusivity. Generally, the concentration 
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of drug in gut is several orders higher than that across the membrane. Decreased particle 
size, increased solubility, prolonged GI tract residence time will increase the dissolution 
number [5]. A higher dissolution number is in favor of increase of drug absorption.  For 
dose number (Do), it equals dose concentration divided solubility, see Equation 1-3. 
 
Dose number (Do) = ୑/୚଴େୱ  (Eq. 1-3) 
 
M is the dose of the drug and V0 is water needed to take the dose, generally 250 
ml is set as default. Cs is drug solubility.  For a given dose, increasing the water amount 
to take the drug or increasing drug solubility will reduce the dose number which favors of 
drug absorption.  
 
By analysis and summarization of permeability and fraction absorbed of 18 drugs, 
(see Figure 1-1) [1], the relationship between drug fractions of absorbed and 
permeability is described as Equation 1-4. 
 
Fa =1-e-2An (Eq. 1-4) 
 
In this equation, the assumption is that the drug is soluble in the GI tract. Basically, it 
applies to class I and class III compounds. In this case, absorption number (An) and 
permeability are two primary parameters to predict oral absorption.  The absorption 
number (An) can also be expressed as drug residence time in intestine divided by drug 
absorption time. See Equation 1-5, which is derived from Equation 1-1. In Equation  
1-1, the unit of Peff is cm/s which likes velocity; R is radius of gut, which likes distance; 
since time equals distance / velocity, the time of drug absorption equals radius of gut / 
permeability that is the reciprocal of Peff/R, too. 
 
Absorption number (An) = <Tsi> / <Tabs> (Eq. 1-5) 
 
 
 
 
 
Figure 1-1. Correlation between human permeability and fraction dose absorbed.  
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When residence time (Tsi) equals absorption time (Tabs), absorption number (An) 
is 1 from Equation 1-5, substituting An=1 in Equation 1-4, Fa is calculated around 86%. 
Return to definition of high permeability, Fa should be no less than 90%. If calculating 
An from Equation 1-4, it will be bigger than 1. The physical meaning of An>1 is that 
drug absorption time is shorter than residence time. As long as the drug dissolves in the 
GI tract, the drug will be absorbed. The above discussion is applied to BCS class I and III 
compounds.  
 
For BCS class II compounds, those drugs are poorly water soluble and GI fluid is 
not enough to completely dissolve them. In this case, Equation 1-6 is derived to describe 
the relationships between solubility, permeability, dissolution and drug absorbed [3, 4]. 
Since Fa always equals or less than 1, Do ≥ 2An.  
 
Fa = 2An/Do (Eq. 1-6) 
 
The concentration of these drugs in GI tract is equal to their solubility. The 
assumption of Equation 1-6 is dissolution rate should be faster than the rate of drug 
absorbed across the intestine membrane. Dissolution rate is the limited factor for these 
drugs oral absorption. For class II drugs, dissolution number (Dn) is commonly less than 
one. 
 
At a given absorption number An, the relation between Do and Dn can be 
described by Figure 1-2 [1]. In Figure 1-2, An is fixed as 10 which means the drug is 
high permeability. Dose number (Do) and dissolution number (Dn) decide drug fraction 
of absorbed. From Figure 1-2, we can see that a low dose number and high dissolution 
number nearly always gave higher drug absorption. The change in Dose number is 
decided by water volume and solubility of drug. More water to take drug can decrease Do 
but this tool is limited by patient compliance and stomach volume capacity; increasing 
drug solubility can be a way; dose number is not commonly changed which is decided by 
physicochemical properties of compound and also decided by its pharmacodynamic and 
pharmacokinetic properties. For dissolution number (Dn), the higher dissolution number 
will result in higher fraction of drug absorption. Some formulation strategies can be 
applied: decrease particle size or increase dissolution rate. Two examples are shown in 
Figure 1-2. For digoxin, the Dn is between 0.1~1.0, Do is around 0.4 and the fraction 
drug absorption is around 0.4. Digoxin is a low dose drug, 0.5mg/dose, when particle size 
is decreased sufficiently, the dissolution rate increased so that the tablets and its hydro-
alcoholic solution were bioequivalent. But for piroxicam, Do is around 12 and Dn is less 
than 0.1, its Fa is less than 0.2. To dissolve the dose, 2857 ml water is needed. For this 
drug, solubility is the limitation for drug absorption. Enhancment of solubility can 
provided sufficient drug amount for absorption [6, 7].  
 
 
1.1.2 Determination of solubility  
 
 Compound aqueous solubility can be seen as a capacity to form hydrogen bonds 
with water molecules. Or it can be seen as how easily its constituent atoms are  
 4 
 
 
 
Figure 1-2. Relationship between Dn, Do and An.  
 
 
surrounded (form hydrogen bonds) by water molecular network. Solubility is measured 
when an excess amount of drug is dissolved in aqueous media, which can be water for 
neutral drug or buffer for weak acid or base, at a certain temperature and pressure [4].  
Analysis is commonly an HPLC or other specific method. The common definition of the 
degree of solubilization is described as in USP:  
 
 Very soluble: Less than 1 part solvent needed to dissolve 1 part solute 
 Freely soluble: From 1 to 10 parts solvent needed to dissolve1 part solute 
 Soluble: From 10 to 30 parts solvent needed to dissolve 1 part solute 
 Sparingly soluble: From 30 to 100 parts solvent needed to dissolve 1 part solute 
 Slightly soluble: From 100 to 1000 parts solvent needed to dissolve 1 part solute 
 Very slightly soluble: From 1000 to 10,000 parts solvent needed to dissolve 1 part 
solute 
 Practically insoluble: More than 10,000 parts solvent needed to dissolve 1 part 
solute     
 
 
1.1.3 Determination of permeability 
 
After drug dissolution in the GI tract, it is ready for crossing the gut membrane. 
The drug mass crossing membrane would subsequently enter the blood. The permeability 
indicated how easily and how much of drug crosses membrane in a given time. An In 
vitro cell line method and in vivo or in situ intestinal perfusion method are accepted by 
regulatory agency for determination of permeability [8].  Both methods need compound 
with known permeability as internal standard or reference drug.  
 
The Caco-2 model is widely accepted and applied to measure in vitro 
permeability. The cell line Caco-2 is from human colonic cancer cells and used in 
transport system research from the 1970s [9]. It can differentiate and form polarized 
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monolayer with tight junction between cells. These properties are similar with that of 
intestinal cells. Moreover, Caco-2 cells have several transport systems: including amino 
acid, vitamin B, glucose, bile acid, small peptide transporters and P-glycoprotein efflux 
system. Figure 1-3 (Modified from Ref. [10]) shows a Caco-2 cell permeability model. A 
drug or reference solution is added to the upper compartment, and then incubated for 
hours. A sampling point is set to derive a mass transport per time (dm/dt) curve for 
permeability calculations. For the Caco-2 permeability calculation, see Equation 1-7. 
 
Peff = (dm/dt) / (A × C0× 60) (Eq. 1-7) 
 
In this equation, Peff is the effective permeability in cm/sec, m is mass across the 
membrane, A is surface area (cm2) for transport, C0 is the slope of best fit line for the 
curve dm/dt, C0 is the initial drug concentration (µM). If the Peff of a drug is higher than 
2×10-4 cm/s, then complete drug absorption will be considered, otherwise, drug 
permeability is low and the absorption is incomplete[11]. 
 
Another widely used method is in situ single-pass (closed loop) rat perfusion 
model. Similar toCaco-2 cell model, an internal standard or reference compound is also 
required. See Figure 1-4, from Ref. [12] for in situ perfusion rat model diagram.  
 
The segment of small intestine (about 6-8 cm) is cut from gut with fully blood 
supply. One end is cannulated to allow for drug injection by syringe. The other end is 
connected with a tube for sample collection. The remaining drug in the intestine is 
collected in a sample vial for concentration measurements by LC-UV or LC-MS. The two 
ends of remaining intestine are tied off by a silk suture. The rat moves freely in a 
restraining cage during experiment. After experiment, the animals are euthanized. This 
model is accepted by the FDA as a tool to determine permeability, regional disposition, 
 
 
 
 
 
Figure 1-3. Caco-2 cell permeability model diagram. 
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Figure 1-4. Intestinal perfusion model.  
 
 
mechanisms of absorption and excretion of drugs, etc [9]. The Permeability calculation 
for this model is shown in Equation 1-8. 
 
Peff = [-Qin ln (Cout / Cin)] / 2rL (Eq. 1-8) 
 
Where Cout and Cin correspond to the drug concentration out of the intestine and 
the drug concentration flowed in intestine respectively. While r is the rat intestinal radius 
which is set to 0.18cm; L is the length of isolated intestine, commonly 6~8 cm [13]. Q is 
the flow rate through the intestine.   
 
Sometimes, for generic drug applications, sponsors provided permeability 
determined by Caco-2 model and in the situ single-pass (closed loop) rat perfusion 
model.The results from two models can be similar in some cases, but also can be 
different. The advantage of the Caco-2 cell model is its cost savings: the cell culture is 
cheaper than animal studies and the experiment can be designed for high throughput 
compound screening. The disadvantage includes Caco-2 cells that are from a colonic cell 
line that is differentiated into small intestinal –like tissue. Actually its tight junction 
between cells is more like colonic cells than small intestine cells which can cause a 
permeability under-prediction for low absorption drugs [14]. Secondly, it may not 
express proper transporters as a true small intestine cells would be expected to.  
 
As a result of disadvantages in Caco-2 model, the more accurate in situ rat 
perfusion model is often introduced for permeability determinations. Thus, for biowaiver 
purpose, sponsors may provide animal permeability result as supplement if the Caco-2 
model under-predicts permeability [9]. 
 
 
1.1.4 Determination of dissolution 
 
The priority condition for oral drug absorption is the dissolution of drug at the site 
of absorption. The Noynes-Whitney equation (Equation 1-9) described the variables that 
can affect drug dissolution:  
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dm/dt = DS (Cs – Ct)/ Vh (Eq. 1-9) 
 
In the equation, dm/dt is the dissolution rate, which means the change in the 
amount of drug dissolved (m) per unit time (t); D is the diffusion coefficient which 
related to temperature, solute radius and viscosity of diffusion medium. S is the surface 
area; h is the thickness of the diffusion film adjacent to the dissolving surface; Cs is the 
saturation solubility of the drug molecule; Ct is the concentration of the dissolved solute; 
and V is the volume of the dissolution medium. From the equation we can see, increasing 
surface area as particle size decreases, or increasing saturation solubility can both 
increase dissolution rate [15]. If dissolution of drug is faster than its gastric emptying, 
(this point is true for BCS class I drugs), basically, dissolution won’t influence the 
bioavailability of drug. For this type of drugs, they can express the similar bioavailability 
but their dissolution can be different. In this case, the gastric emptying rate will be the 
limiting factor for drug bioavailability (BA). For BCS class I drug, in vivo in vitro 
correlation (IVIVC) could be constructed [16].  
 
For BCS class II drugs with low solubility and high permeability, dissolution rate 
and extent can both be the rate-limiting factor to drug absorption. Dissolution rate can be 
increased by decreasing particle size; where extent of dissolution increase depends on 
solubility enhancement which can be introduced by many new techniques besides adding 
surfactant in formulation.   
 
 Class I:  High Solubility – High Permeability   
 Class II:  Low Solubility – High Permeability   
 Class III:  High Solubility – Low Permeability   
 
For BCS class III drugs with low solubility and high permeability, they are easily 
soluble as class I drug; it is gastric emptying rate rather than dissolution rate that affect 
more on BA. The low permeability is the limiting factor for their oral absorption. If the 
drug absorption occurs as linear process, increasing dose is a way to increase 
bioavailability. Or if P-glycoprotein pumped the drug out of membrane, then the P-
glycoprotein inhibitor may be added in formulation to inhibit its efflux function [3]. 
 
Drugs with low solubility and low permeability are categorized to BCS class IV. 
These compounds have poor oral bioavailability and are not easy to develop oral dosage 
form. Generally, non-oral dosage form will be considered for BCS class IV compound. 
However, there are still few oral BCS class IV drugs on market: hydrochlorothiazide, 
taxol, and furosemide. 
   
For oral dosage forms after administration, the drug is passed into stomach, 
disintegrates here, then drug dissolves to allow absorption. Simulated gastric fluid (SGF) 
is commonly used as a dissolution media. Since the small intestine is the major area for 
most drug absorption, simulated intestine fluid (SIF) is another commonly used 
dissolution media. When developing dissolution method for BCS class I or class III 
drugs, a volume of 900 ml can provide sink condition for those drugs dissolution; 
surfactant maybe added in SGF or SIF to make sink condition for BCS class II or class 
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IV drugs. Besides the aforementioned dissolution media, other bio-relevant media are 
prepared for mimic fast state gastric condition, fed state gastric condition, fast state 
intestine condition and fed state intestine condition. In the dissolution media, surfactants 
and enzymes are often also selected as needed [17]. 
 
Basket (USP apparatus I) or paddle (USP Apparatus II) dissolution is the most 
commonly used methods for oral dosage form. The volume of media is generally set to 
900 ml. For high soluble BCS class I and III compounds, the duration time should be 
shorter than that of BCS class II or IV. For IVIVC purpose, the dissolution criteria is set 
by FDA as no less than 85% drug substance is dissolved in three different dissolution 
media (SGF with pH1.2 without enzyme, pH 4.5 buffer and SIF or pH6.8 buffer without 
enzyme); for each formulation, 12 dosage units are evaluated. Sampling points should be 
enough to derive the dissolution curve for comparison [18]. The variance of initial point 
on dissolution curve (like 10min point) should be less than 20%, the following points 
should be within 10% variance. The similarity factor (f2) is required to compare the 
dissolution profiles. See Equation 1-10 for f2 value calculation.  
 
f2=50∙ log	ሼሾ1 ൅ ଵ௡ ∑ ሺܴݐ െ ܶݐሻ௡௧ୀଵ
ଶ]-0.5ൈ 100ሽ (Eq. 1-10) 
 
Where n is the number of time points, Rt is the mean cumulative percent 
dissolved of a reference drug at time t, Tt is the mean cumulative percent dissolved of a 
test drug product at time t. If no less than 85% drug dose dissolved within 30min, f2 
value comparision is not necessary. If 85% drug amount dissolution is longer than 30min, 
then f2 value may be calculated to compare dissolution profiles. Two dissolution profiles 
would be considered similar if f2 ≥ 50 and the difference of two dissolution profile is less 
than 10% [19]. 
 
 
1.2 Formulation Strategies for Poorly Water Soluble Drug Development 
 
Currently, BCS is widely accepted as a must tool in new drug or generic drug 
development. In the early stage of drug development, solubility and permeability of lead 
compounds are measured to decide which category the drug belongs to. Then a 
formulation strategy has been previously used successfully might be considered for this 
compound. For class I compounds, they are easily soluble and have good absorption, 
formulation for these compounds is more likely to be a stability issue than a dissolution 
problem. For class II compounds, a formulation strategy is critical to improve dissolution 
rate if the limiting-step of absorption is dissolution rate or improve solubility if the drug is 
solubility-limiting oral absorption. Micronization, nanotechnology, cyclodextrin 
complexation, lipid based formulation, micellization, microemulsions and solid 
dispersion are accepted approaches to handle poorly solubility issues. It is not easy to 
develop BCS class III compounds because it is hard to change permeation of drug and 
membrane. Some permeation enhancers have been studied for this purpose [20-22]. For 
BCS class IV compounds, approaches for improving solubility and permeability are 
needed at the same time, plus it is necessary to understand the compound absorption 
mechanism and factors affecting bioavailability. Alternative delivery methods, such as 
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i.v. or it may be necessary to go back to lead chemical optimization. Nevertheless, several 
Class IV drugs do exist. Examples include taxol, cyclosporin A and furosemide. In these 
innovative formulation strategies, nanotechnology and lipid based formulations will be 
discussed in the following subtopics, as well as cyclodextrin complexation. Solid 
dispersion approachs will be discussed in details in Chapter 2. 
 
 
1.2.1 Nanotechnology in poorly water soluble drug development 
 
Particle size reduction is an effective tool to enhance the dissolution rate of poorly 
soluble drugs. It is well known that the micronization can increase in vivo absorption and 
bioavailability of poorly water soluble drugs. But micronization works for those drugs 
that oral absorption is limited by dissolution rate. The micro-scale particles are not small 
enough to increase oral bioavailability of those drugs which oral absorption is limited by 
solubility, such as high dose BCS class II drugs. But in the case of reducing particle size 
to nano-scale, the oral BA of aforementioned two type poorly soluble drugs can both be 
enhanced [23]. Some nanosuspensions on market or in clinical trials are listed in below.   
 
Nanosuspensions we will discuss here is a colloidal dispersion of pure drug 
particles in water with other necessary ingredients. The particle size for nanosuspension 
is generally smaller than 300 nm for Brownian motion to keep system stable. Individual 
particle in a nanosuspension cannot be seen by the naked eye. The drug particle in 
nanosuspersion is in a preferred crystalline form with sufficiently small size. Usually, the 
preferred API for this formulation is those insoluble drugs with solubility less than 0.1 
mg/ml. If the solubility is higher than 0.1 mg/ml, other strategies including co-solvent, 
surfactant, emulsion, etc. might be utilized [24].  
 
 
1.2.1.1 Formulation rationale and ingredient function 
 
The constituents of a typical nanosuspension include drug (API), stabilizers, 
surfactants and water. Basically, the nanosuspension is a thermodynamically stable 
system with high energy. The preparation process is a surface area increase process 
which will induce free energy increase. But adding surface-active agents can compromise 
the surface change effect by decreasing interfacial tension, thus keep or decrease free 
energy. This basic principle can be shown Equation 1-11, where G is change of free  
 
G = s/l •A (Eq. 1-11),  
 
energy, s/l is the interfacial tension between solid (particle) and liquid (water), A is the 
change of surface area. Generally, two type surface-active agents: ionic surfactant and 
non-ionic surfactant are used in nanosuspensions [25].  Function of polymer and 
surfactant in preparation and stabilization of nanoparticles is shown in Figure 1-5, 
modified from ref. [25]. 
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Figure 1-5. Function of polymer and surfactant in nanoparticles. 
 
 
In Figure 1-5, for the case of circle a, hydrophobic crystal surface directly 
contacting water molecules leads to crystal agglomeration. For the case of circle b, 
polymer and surfactant synergy stabilized crystal surface, the stabilizers not only reduced 
contact opportunities between water and crystal particles, but also decreased interfacial 
tension by attraction between water and surfactant. In a nanosuspension, two close 
nanoparticles tend to agglomerate because of Van Der Waals attractive forces or 
hydrophobic attraction, but with a polymer and surfactant in the system, the trend can be 
reduced by steric repulsion or electrostatic repulsion from exicipient.  
 
This point can also be interpreted as polymer molecules inserted into API 
particles thus increasing the distance of two hydrophobic particles and decreasing their 
hydrophobic attraction. When adding ionic surfactants, these molecules attached at the 
interface of water and nanoparticles to not only reduce the interfacial tension (s/l), but 
also incur static repulsion to prevent crystal growth and particle agglomeration.   
 
Commonly used polymer and surfactant include cellulose derivatives; poloxamer, 
polysorbates, transcutol, etc. are shown in Figure 1-6. Selection of exicipients will be 
according to the properties of API [26]. 
 
 
1.2.1.2 Nanosuspension preparation methods 
 
The first successful scale-up nanosuspension manufacture technique is owned by 
Elan Drug Delivery. It is media mill. The mechanical diagram is shown in Figure 1-7. 
 
The API particles (after premilling by ball mill or micronized API) are mixed 
together with selected surfactants and polymer in water, then place the suspension in the 
chamber which is charged by milling media, a drive shaft attached to rotating disk to 
make it rotate at a very high shear rate. A cooling system is included to make the whole 
process under controlled temperature. In process, particle size is determined by stress 
intensity and the number of contact points between API crystal and media grinding 
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Figure 1-6. Relation in nanoparticles, polymer, surfactant and water molecules. 
 
 
 
 
 
 
Figure 1-7. Schematic representation of the media milling process.  
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beads. After milling 30 ~ 60 min, the particle size can be reduced to 200 nm with narrow 
distribution. The variance among batches is very small ( 2%) [23]. 
 
High pressure homogenization is another technique that applied to prepare 
nanosuspension from lab to manufacture scale. The schematic diagram of this piston-gap 
homogenizer is shown in Figure 1-8. For this method, pre-suspension is necessary before 
preparing nanosuspension. The pre-suspension, usually a micronized, particle size which 
can be smaller than 5 µm, placed in the chamber to pass through a narrow channel 
(homogenization gap), the flow velocity is increased tremendously under high pressure 
(1400 bar). According to Bernoulli principle, simultaneously static pressure of pre-
suspension fluid decreased which reduced the boiling point of water, then water start to 
evaporate to form bubble in the boiling area. At the same time, the pre-suspension goes 
through the channel (e.g. 25 µm), then water bubble implodes when fluid leaves channel 
due to the pressure change (cavitations effect). The energy produced from cavitations’ 
cracked the fluid into nanoparticles. In this method, suspension needs to be micronized in 
case big particles occlude the narrow channel. Homogenization pressure and numbers of 
homogenization cycles are keys for final product quality [23, 27, 28]. 
 
Other methods include crystal precipitation, emulsion or microemulsion as 
templates to prepare nanosuspensions. The drug will be first dissolved in a solvent or co-
solvent, then form nuclei at slow speed by adjusting temperature, then optimizing 
temperature for crystallization at a fast speed to keep the size of crystals in nano-scale. 
During this crystal precipitation process, the control of temperature is the key. When 
preparing nanoparticles from emulsions or microemulsions, the first step is to form a 
stable emulsion, then agitate water phase under high stirring speed, the solvent 
evaporated, solid particles obtained. Surfactants are necessary in the process [28].  
 
 
 
 
 
Figure 1-8. Schematic diagram of homogenization process. 
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1.2.1.3 Characterization and key factors affecting product quality 
 
Particle size distribution, stability and bioavailability are three critical factors 
affecting the quality and efficiency of nano-suspensions. Laser light diffraction is used to 
analyze the drug substance in aqueous nano-suspensions. In data calculation, Fraunhofer 
and Mie therories are employed. The former one is the default for particle size 
calculation. In the USP, if particle size is smaller than 25um, Mie theory can also be 
applied. If inconsistent results occurred, other techniques such as scanning electronic 
microscopy (SEM) and Mie theory will be applied. XRPD is also used to characterize the 
solid form or polymorph. Stability is tested under the accelerated condition to see if 
agglomeration occurred, shipping conditions are also evaluated, too. Bioavailability is 
determined by conducting bioavailability and pharmacokenetic studies; Cmax, Tmax and 
AUC are compared to reference formulations [29, 30]. 
 
 
1.2.1.4 Commercial products and promising drug product status 
 
Currently commercial products include tablet, suspension and capsule. Rapamune 
is an immune-suppressant tablet based on Elan nano technique which is manufactured by 
Wyeth. Merck also has one nanoparticle product: Emend which is anti-emetic drug in 
capsule form applying Elan nano technique too. In addition to aforementioned drugs, 
there are several drugs on every stage of clinical trial [31]. 
 
 
1.2.2 Self-emusifying drug delivery system 
 
Several type of drug formulation system can be categorized as lipid based drug 
delivery systems. These formulation approaches also target to deliver poorly water 
soluble drugs. Self-emusifying drug delivery system (SEDDS) is one of these 
approaches. Excipients including oil, co-solvent and surfactant are mostly often 
considered in this system. The mixture of oils, surfactant, and often drug co-solvents are 
supposed to be isotropic. When the whole system contacts with water in vitro or in vivo, 
the oil in water emulsion will be formed and drug is released [32]. 
 
 
1.2.2.1 Basic principle and excipient function 
 
The exactly mechanism of how the system works is still a remaining work for 
discover. But commonly reorganization is the relationship among liquid crystal 
formation, oil-water phase inversion temperature, the increased water solubility by lipid 
formulation that affects the self-emusifying efficiency. The equilibrium phase diagram is 
the priority part for the SEDDS development. The oil is the most important ingredient in 
the SEDDS which is used as drug solvent and oil phase, sometimes, a co-surfactant will 
be selected to work together with oil to dissolve more drugs. Both long and medium 
chain triglyceride oils are candidates. In SEDDS, food oils are not frequently used due to 
the low efficiency in dissolving API and long term stability issue [33]. 
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The most commonly used surfactants in SEDDS are non-ionic surfactants which 
have high hydrophilic-lipophilic balance (HLB). Ethoxylated polyglycolyzed glycerides 
and polyoxyethylene 20 oleate (Tween 80) are two types of widely used surfactants. The 
usual amount of surfactant in SEDDS is about 25~60%. The high usage amount of 
surfactants may induce a toxicity problem which is a major concern in surfactant 
selection. Even with Tween 80, it may cause GI irritation when used in long chronic 
application. Considering the toxicity issue; the choice of surfactant will be generally 
limited to the aforementioned two types. The type and amount of surfactant are two 
critical parameters to develop a good formulation. In SEDDS, surfactant is incorporated 
in the interface of oil and water, to help form micelles or fine-emulsion. With surfactant, 
the interfacial tension between water and oil can reach ultra-low values which will 
benefit drug stabilization in oil and fast dispersing when met with large amount water or 
fluid, such as in the GI tract [34]. 
 
The co-solvent is also a critical ingredient in SEDDS. Propylene glycol (PG), and 
polyethylene glycol (PEG) are two poplar so-solvents. It helps to dissolve API and 
quickly disperse SEDDS to form fine oil in water emulsion in drug dissolution and 
absorption. 
 
 
1.2.2.2 Phase diagram and characterization tools 
 
A phase diagram is the first step to develop a SEDDS. Usually the constituents of 
oil, co-solvent, surfactant and water without drug will be first tested at room and 
physiogical temperature to construct a phase diagram. An initial ratio between oil, co-
solvent and surfactant will be assigned empirically as a starting point; the proper ratio 
among of oil, cosolvent and surfactant will be decided from the first phase diagram. Then 
the optimized ratio between oil and cosolvent is set as one component to construct second 
three phase diagram or pseudo three-phase diagram. A typical three-phase diagram is 
shown in Figure 1-9. A series of screening experiments is necessary to construct it. The 
triangle line is single phase line; the line inside is two components equilibrium line, two 
components are miscible in this line; the gray area inside triangle is the miscible area of 
three components which is what we need. Basically, the mix ratios of components in the  
gray area can be selected to further incorporate drug. According to drug dose and loading 
amount, the ratio among oil, co-solvent and surfactants would be adjusted [32, 35]. 
 
Upon dissolution, when SEDDS meets water or fluid in GI tract, it should 
disperse quickly and form fine oil in water emulsion. The co-solvent in the system assists 
the quick dispersion and large amount of surfactant is quickly distributed at the interface 
between oil and water to decrease the interfacial tension. Drug is kept in oil and ready for 
absorption [33, 36]. 
 
Upon dissolution or when the drug entered GI fluid, precipitation problems 
happen occasionally this is the intrinsic property of SEDDS. In that case, phase 
equilibrium is broken and drug can precipitate out. Phase break can be induced by 
temperature change, such as temperature changed from room to physiological condition,  
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Figure 1-9. Scheme of typical three-phase diagram under isothermal condition. 
 
 
cloud point reached; or induced by inability of the system to contain the drug under the in 
vivo conditions. 
 
 
1.2.2.3 Commercial products 
 
Several marketed products are applied SEDDS in their formulation and clinical 
practice shown benefit over side effect of high amount of surfactant.  These drugs are 
summarized in Table 1-1, including major ingredients of each formulation [37, 38].   
 
 
1.2.3 Cyclodextrin application in drug delivery 
 
Cyclodextrin are cyclic oligosaccharides of glucose. Usually when one molecular 
cyclodextrin contains 6, 7 or 8 glucose molecules, these oligomers will be referred to as 
α, β or  cyclodextrin. The cylinder shape molecules have amphiphilic properties that can 
form water soluble complex with small molecules and specific portion of large 
molecules. The shape and complex of cyclodextrin diagrams are shown in Figure 1-10.  
 
The outside of cylinder is hydrophilic which incur the water solubility to 
cyclodextrin, the inside cavity is hydrophobic which form complex with poorly water 
soluble drug, thus increase the apparent solubility of drug, then further increase the 
bioavailability. It can also benefit the drug stability, prevent degradation of compound 
[39, 40].  
 
The first cyclodextrin was discovered in 1891 and the first patent of cyclodextrin 
in drug formulation was issued to Freudenberg et al. in 1953. After that, the research on 
cyclodextrin became hot area for some years. During these years’ study, the chemical 
properties including determination method, molecular structure characterization, drug 
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Table 1-1. Summary of commercial SEDDS drug products. 
 
Trade name Generic name Dosage form Surfactant Solvent Oil Company Approval date
Sandimmune® Cyclosporine A Soft gelatin capsule 
Linoleoyl 
macrogolglycerides 
(polyoxylglycerides)
Alcohol Corn oil Novartis 2-Mar-90 
Neoral® * Cyclosporine A Soft gelatin capsule 
Cremophor RH 40 
(HLB 14~16) Ethanol 
PG/Corn oil mono-
di-triglycerides/ α-
tocopherol 
Novartis 14-Jul-95 
Norvir® ritonavir Soft gelatin capsule 
Cremophor EL       
(HLB  12~14 ) ~13%
Ethanol 
12% Oleic acid 75% 
Abbott 
laboratories 10-Feb-10
Fortovase® Saquinavir Soft gelatin capsule NA Povidone
Medium chain 
mono- and di-
glycerides, DL-α-
tocopherol 
Hoffmann‐La 
Roche lnc. 24-Dec-03
Agenerase® Amprenavir Soft gelatin capsule TPGS (HLB ~13) PEG 400
PG (phosphatidyl 
glycerol ) Glaxosmithkline 5-Feb-02 
* Neoral® is not bioequvelent with Sandimmune®, it has high bioavailability than Sandimmune®. 
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Figure 1-10. Schematic diagram of cyclodextrin-drug complex. 
 
 
solubilization mechanism, complex form capacity are thoroughly disclosed. Besides 
chemical structure and function, biology, pharmacokenetics, pharmacodynamics and 
toxicity in human and animal are also studied. These researches found renal toxicity of 
cyclodextrin when administered i.v. Oral applications do not have renal toxicity since 
enzymes excreted from pancreas and stomach can degrade cyclodextrin. But fortunately, 
chemical modifications done to original cyclodextrins reduced toxicity and made it safe 
to be used as a solubilizer for i.v. Modified cyclodextrin not only improved the safety but 
also the aqueous solubility. The solubility of α, β or  cyclodextrin in water at ambient 
temperature is 13%, 2% and 26% w/w respectively, whereas modified cyclodextrins have 
increased solubility which can reach to 60% w/w or even more. Currently, application of 
cyclodextrin have become a common solution for formulators to solve solubility problem 
of poorly water soluble drugs in various administration routes, including oral, 
ophthalmic, i.m., i.p., etc. Two modified β-cyclodextrins: hydroxypropyl-β-CD (HPβCD; 
Figure 1-11) and sulphobutyl ether derivatives of β-CD (SBEβCD; Figure 1-11) are 
widely accepted as i.v. excipient by regulatory agency in many countries [41]. 
 
Cyclodextrin are successfully used as drug solubilizers and have made 
commercialization of many drugs possible. Table 1-2 summarized marketed drugs with 
cyclodextrins [39]. Cyclodextrins do have some disadvantages, such as low drug loading 
which limits its application to lower dose potent drugs and a relatively high price. 
 
 
1.3 Summary 
 
Based on BCS classification, drugss are divided into four categories. For class II 
and class IV, the drug solubilization is a critical issue for product development. The 
selection of formulation strategies can be various, from simple to complicated, from low 
to high price. The screening sequence can follow: co-solvent, alcohol, lipids; or new 
techniques, such as SEDDS, nanosuspension, solid dispersion. But for those new 
techniques, each has its own advantage and disadvantages. The benefit-risk or benefit-
economy would be evaluated for a decision. The solid dispersion technique will be 
discussed in detail in Chapter 2.  
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Figure 1-11. Graphic diagram of HP-β-CD and SBE-β-CD.  
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Table 1-2. Summary of drug products using cyclodextrin.  
  
Drug Administration route Trade name Market 
Alprostadil (PGE1) Intravenous Prostavastin, Caverject, Edex 
Europe, Japan, United 
States 
Cefotiam hexetil HCl Oral Pansporin T Japan 
Limaprost Oral Opalmon, Prorenal Japan 
β-Cyclodextrin  (βCD) 
Benexate  HCl Oral Ulgut, Lonmiel Japan 
Cephalosporin Oral Meiact Japan 
Cetirzine Oral Cetrizin Germany 
Chlordiazepoxide Oral Transillium Argentina 
Dexamethasone Dermal Glymesason Japan 
Dextromethorphan Oral Rynathisol Europe 
Diphenhydramin and 
chlortheophyllin Oral Stada-Travel Europe 
Ethinylestradiol and 
drospirenone Oral Yaz Europe, United States
Iodine Topical Mena-Gargle Japan 
Meloxicam Oral and Rectal Mobitil Egypt 
Nicotine Sublingual Nicorette Europe 
Nimesulide Oral Nimedex, Mesulid Europe 
Nitroglycerin Sublingual Nitropen Japan 
Omeprazole Oral Omebeta Europe 
Dinoprostone (PGE2) Sublingual Prostarmon E Japan 
Piroxicam Oral Brexin Europe 
Tiaprofenic acid Oral Surgamyl Europe 
Cisapride Rectal Propulsid Europe 
Hydrocortisone Buccal Dexocort Europe 
Indomethacin Eye drops Indocid Europe 
Itraconazole Oral, intravenous Sporanox Europe, United States
Mitomycin Intravenous Mitozytrex United States 
Randomly methylated β-CD 
17β-Oestradiol Nasal spray Aerodiol Europe 
Chloramphenicol Eye drops Clorocil Europe 
Sulphobutylether β-CD 
Aripiprazole Intramuscular Abilify United States 
Maropitant Intravenous Cerenia United States 
Voriconazole Intravenous Vfend Europe, United States
Ziprasidone maleate Intramuscular Geodon, Zeldox Europe, United States
Diclofenac sodium Eye drops Voltaren Europe 
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CHAPTER 2.    SOLID DISPERSION REVIEW 
 
 
This chapter is intended to combine recent literature on solid dispersion 
technology for solubility enhancement with various preparation methods, evaluation 
parameters and commonly used polymer carriers. Solubility behavior is one of the most 
challenging aspects for drug commercialization or one of the main reasons for a drug that 
does not reach to its full potential. Currently, nearly 60% of new chemical entities 
possess solubility problems, whereas practically no drug products with less than 10 μg/ml 
solubility in 70’s or 80’s. Various techniques have been applied to enhance drug 
solubility such as the use of co-solvents, particle size reduction, lipid based drug delivery 
systems, nanosuspensions, use of surfactants, salt formation, cyclodextrin complexes and 
solid dispersions etc. In this chapter, several drug products using solid dispersion 
techniques are also reviewed.  
 
 
2.1 Definition and History of Solid Dispersion 
 
Chiou and Riegelman have defined solid dispersions in 1971 as “a dispersion of 
one or more active ingredients in an inert carrier at the solid state, prepared by the 
melting, the solvent or the melting solvent method” [42]. A solid dispersion consists of at 
least two components: hydrophilic matrix and hydrophobic drug. The matrix can be 
either crystalline or amorphous in structure. In 1971, solid dispersion was summarized as 
the following 6 types [42]: group 1, simple eutectic mixtures; group 2, solid solutions: a 
solid solute dissolved in a solid solvent, two components crystallize together in a 
homogeneous one-phase or more than one phase system; group 3, glass solutions and 
glass suspensions, the solute dissolved or dispersed in the glassy solvent; group 4, 
amorphous drug was dispersed in crystalline carrier; group 5, complex formation between 
the drug and the carrier; group 6, any combination among groups 1-5. From the point of 
physical state of drug in solid dispersion, drug was crystalline in simple eutectic mixture; 
in glass solutions, the drug and the carrier were both amorphous form. However, over the 
years, new formulation techniques for poorly soluble drugs made the line of classification 
less clear. The nanosuspension can be absorbed in solid absorbents to make nanoparticles 
dispersed and stabilized in solid matrices. Cocrystals can be classified into solid solutions 
and in lipid formulations or self-emulsifying drug delivery systems, drug can also be 
dispersed or dissolved in solid matrices [43]. The schematic diagram of the classification 
system and the new techniques overlap with it is shown in Figure 2-1. Nowadays, most 
solid dispersions are glass solutions or glass suspensions in which a hydrophilic polymer 
with high glass transition temperature was selected as carrier material and the drug can be 
molecularly dispersed or precipitated as amorphous form in the carrier [44]. The 
crystallization process can be prevented by the viscous medium.  
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Figure 2-1. Scheme of solid dispersion classification system and new techniques. 
 
 
2.2 Dissolution Rate or Solubility Enhancement Mechanism from Solid Dispersion 
 
According to the preparation method, a number of strategies can be adapted to 
increase solubilization of poor water soluble drug and its dissolution rate in dosage form. 
 
 
2.2.1 Enhanced wettability 
 
A hydrophilic material as solid dispersion carrier can be utilized drug dissolution 
enhancement. The fast hydration of the surface of one phase solid dispersion system 
allows water to easily contact with the drug and the drug quickly release from dosage 
form [45]. Carriers with surface activity, such as surfactants can significant decrease the 
interfacial tension between dissolution medium and surface of dosage form, which also 
results in enhanced dissolution rate. The drug loading or the ratio between drug and 
carrier has a strong effect in the wettability of solid dispersions. Generally, a low drug 
loading or a high amount of polymer used in solid dispersion demonstrated better 
wettability [46, 47].  
 
 
2.2.2 Particle size reduction 
 
In a melt-quench method, drug and carrier are melted together and then quenched 
to form hard clump as one phase system. In the solvent evaporation method, drug and 
carrier are dissolved in common solvent and then evaporated rapidly. Solid dispersion 
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clumps or powders left for further processing. In either of the two preparation methods, 
the drug is dispersed in the carrier at a molecular level. No distinguished drug particles 
can be observed in the solid dispersion. When drug releases from solid dispersion in 
aqueous media, the increased specific surface area of drug can be help to form colloid 
solution resulting in higher dissolution rate [43].   
 
 
2.2.3 Reduced aggregation and agglomeration 
 
Particle size reduction increases surface area of particles, thus it can improve the 
drug dissolution rate. However, for the pure fine particles (0.1 µm), aggregation and 
agglomeration may commonly occur. Since the specific area of fine particles increases 
tremendously, the Van der waal’s attraction and electrostatic charge among particles 
increases to cause particles to agglomerate and aggregate. When those pure fine particles 
meet with dissolution media, their poor water wettability properties made them dissolve 
slower than that of more coarse particles. In solid dispersions, this problem is overcome. 
The hydrophobic drug particle is surrounded by a matrix which prevented the 
hydrophobic attraction efficiently thus reduced the agglomeration or aggregation of 
particles [42]. The dissolution rate of a solid dispersion has been enhanced by the aid of 
solid dispersion hydrophilic carrier material. Various hydrophilic polymers form solid 
dispersion with poor water soluble compound demonstrated this point [48, 49]. 
 
 
2.2.4 Amorphous state of drug 
 
Compared to its crystalline counterpart, the amorphous form of drug does not 
have a defined structure, and lower intramolecular or intermolecular attraction. Thus no 
energy is required to break crystal lattice in the amorphous state during dissolution. These 
properties allow the system to be easily hydrated and dissolved in water. The higher 
solubility promotes a fast dissolution rate [50, 51]. The maintenance of supersaturation 
state of drug in dissolution media or GI tract is the major reason to promote a fast 
dissolution rate to achieve better bioavailability. The amount of polymer used in solid 
dispersion affects the drug supersaturation state significantly, the more polymer used, the 
higher degree of supersaturation [52]. Thus, using the advantage of amorphous form, 
keeping it stable and preventing its recrystallization has been a critical issue in 
formulation development. Selection of the carrier polymer, its ratio to drug, as well as 
preparation method play important role in a successful solid dispersion dosage form. 
More and more research demonstrated that the major mechanism of solid dispersion was 
the amorphous state of drug.  
 
 
2.3 Preparation Methods    
 
Traditionally, three basic methods have been used to prepare solid dispersion 
which is melting or fusion, solvent evaporation, and melting combined solvent 
evaporation method [42]. From the first solid dispersion formulation: sulfathiazole-urea 
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solid dispersion published by Sekiguchi [43] in 1960s’ till now, the research of solid 
dispersion is constantly expanding. The concentrated research has encouraged the 
emergence of many novel methods to prepare solid dispersion in lab scale, pilot and 
scale-up to manufacture size. The hot melt extrusion approach and spray drying 
technique have made solid dispersion dosage form commercialization possible. The two 
techniques have been the major processes in solid dispersion drug product manufacture.     
 
 
2.3.1 Hot melt extrusion 
 
The principle is co-melting or co-fusion: drug and carrier were heated together 
until melting to a clear liquid, and then quenched the melt to get solid dispersion. This 
method was first described by Sekiguchi and Ovi [53]. They prepared solid dispersion by 
melting the sulfathiazole-urea mixture, cooling the melt in an ice bath, and then the hard 
cooled melt was pulverized into powder. Nowadays, many solid dispersion experiments 
conducted in laboratories still use this method. Hot melt extrusion is an industrial 
applicable variation of the melting or fusion method. A specific machine has been 
designed and applied for this purpose. Hot melt extrusion equipment is commercially 
available from laboratory scale or manual operation to manufacturing scale or automatic 
operation. The procedures described below for the preparation of solid dispersion using 
hot melt extrusion. A powder blend of drug and polymer carrier is introduced into a 
heated barrel via hopper. A single-screw or twin-screw is installed in the barrel where the 
powder blend is intensively mixed, heated and moved to a shaping part which shapes the 
soft materials as granules, small cylinders, or films via various dies. Then the outcome of 
hot-melt extrusion will be further processed into a capsule or tablet. The simple flow 
chart of this procedure is shown in Figure 2-2. The feeding hopper, barrel with screw 
inside, die system and engine are the basic components consist of hot melt extrusion. A 
schematic diagram of hot melt extrusion is shown in Figure 2-3, modified according to  
[54]. 
 
In the heating barrel, a single screw or twin screw is installed to move the mixing 
melt. Compared to the single screw extruder, the twin screw extruder has some 
advantages: material can be fed easier and quicker; it has high kneading potential and 
material dispensing capacity; it is more efficient heating and mixing make the chance of 
material overheating less and shortens the operation time. Two rotation modes are 
designed for twin screw extruder. The two crews can co-rotate or counter-rotate. The 
commonly used rotate mode is co-rotating which can operate under high screw speed and 
more flexible design in screws. For counter-rotating extruder, a low screw speed is 
preferred since high screw speed will introduce a high pressure and high shear force  
 
 
 
 
 
Figure 2-2. Schematic flow chart of hot melt extrusion process. 
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Figure 2-3. Schematic diagram of components of a single screw extrusion.  
 
 
between screws which has high potential to damage the parts. High speed can also entrap 
air which cause defect in final extrudates [55]. However, the low cost and mechanically 
simplicity of the single screw extruder make it still one of the selections for users.  
 
Several parameters in the hot melt extrusion procedure need to be considered and 
optimized for a specific experimental process. Those parameters include the barrel 
temperature, material feeding rate and screw speed. The melt pressure is decided by other 
parameters. The barrel temperature is decided by the melting point of the drug and the 
glass transition temperature of polymer and it is accurately controlled by instrument in a 
range of 30°C to 250°C. 
 
Besides the application in pharmaceutical industry, hot-melt extrusion is widely 
used in plastic and rubber industry to manufacture pipes, hosed insulated wires and 
cables, etc. In pet food industry, extrusion has been commonly used to produce palletized 
feeds for animals [54]. It has been used in food industry for pasta or ground meat 
production since 1930’s [56].  
 
Solid dispersion prepared using hot-melt extrusion method is used not only in oral 
dosage form development to help in solubilization of poor water soluble drugs but also 
used in transdermal delivery system, implants and sustained release drug delivery system. 
Several marketed solid dispersion drug products are listed in Table 2-1. 
 
Besides marketed drug products, many research papers about solid dispersion 
study using hot melt extrusion technique have been published. The model drugs selected 
in these papers are generally BCS class II or IV compounds.  Only the latest literature 
will be reviewed below since many papers have been covered in former review articles 
[42, 43, 46, 50].  
 
Andrews et al investigated solid dispersion of bicalutamide and PVP prepared by 
hot melt extrusion technology. A single Tg in DSC, no sharp peak diffraction pattern of 
PXRD and enhanced dissolution rate indicated amorphous bicalutamide and PVP solid  
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Table 2-1. Examples of commercial solid dispersions. 
  
Number Drug product Company 
FDA 
approval Technology Drug Carrier 
1 Gris-PEG Pedinol harm Inc. 1975 Melt process Griseofulvin PEG 6000 
2 Cesamet Eli Lilly 1985 Melt extrusion Nabilone PVP 
3 Prograf Fujisawa 1994 Unkown Tacrolimus HPMC 
4 Sporanox J&J 1996 Spray dry onto substrate Itraconazole HPMC 
5 Certican Novartis 2004 Unkown Everolimus HPMC 
6 Kaletra Abbott 2005 Melt-extrusion Lopinavir, ritonavir PVPVA 
7 Isoptin SR-E Abbott 2005 Hot melt extrusion Verapamil HPC/HPMC 
8 Intelence Tibotec 2009 Spray drying Etravirin HPMC 
9 Nivadil Fujisawa Not yet Unkown Nivaldipine HPMC 
10 Incivek Vertex 2011 Spray drying Telaprevir HPMCAS 
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dispersion formed. Moreover, stability test has been done at 20 degrees C, 40% RH and 
20 degrees C, 65% RH for 12 months, no drug crystallized was observed at 40% RH, 
whereas drug crystallized at higher humidity (65% RH). However, drug recrystallization 
after storage did not change the dissolution profile of the solid dispersion [57]. Two 
methods: hot melt extrusion and cogrinding have been applied to prepare ginsenosides 
solid dispersion. In the dissolution test, the solid dispersion prepared by hot melt method 
is better than that of solid dispersion prepared by co-grinding method; however, co-
grinding method showed better bioavailability than that of hot melt method [58]. 
 
 Feng J et al investigated the hot melt solid dispersion of bifendate with three 
polymers: Plasdone® S-630, Eudragit® EPO and Kollidon® VA 64. DSC and XRPD 
indicated that the drug was in amorphous form and dispersed molecularly in the three 
solid dispersions. The drug release from solid dispersions was in the order of bifendate-
Kollidon® VA 64 > bifendate-Plasdone® S-630 > bifendate-Eudragit® EPO, while the 
relative bioavailability tested in beagle dog was in the order of bifendate-Kollidon® VA 
64 > bifendate-Eudragit® EPO > bifendate-Plasdone® S-630. The relative bioavailability 
of bifendate-Plasdone® S-630 solid dispersion was lower than that of commercial pills 
[59].  
 
Jijun F et al using hot-melt extrusion prepared a solid dispersion of nimodipine 
and two polymer mixture: Eudragit EPO and Kollidon VA64. The dissolution result 
showed fast drug release from solid dispersion. PXRD and DSC results showed that drug 
was in amorphous form in solid dispersion. The accelerated stability (40 degrees C, RH 
75%) of solid dispersion tablet was examined for 2 months. Drug dissolution rate was 
slightly decreased after 2 month storage even though no crystalline was observed by 
PXRD [60]. 
 
 Another BCS class II drug: celecoxib has been selected as model drug to prepare 
solid dispersion using hot-melt extrusion with PVP and Eudragit 4155F. Drug 
concentration in dissolution media was significantly higher than its equilibrium 
solubility. But the mechanism for this phenomenon was different for the two solid 
dispersions. For celecoxib-PVP solid dispersion, the supersaturation state and amorphous 
form of drug can be kept in dissolution media by PVP; while for celecoxib-Eudragit 
4155F solid dispersion, the polymer also acted as solubilizer that increased the 
equilibrium solubility of drug [52]. 
 
Two polymers Eudragit E100 and PVP-VA have been selected to prepare solid 
dispersion using hot-melt extrusion for fenofibrate which is a BCS class II drug. DSC and 
X-ray diffraction showed that the compound was in amorphous form in the two solid 
dispersions. The results of drug release in 0.1M HCl and water showed that Eudragit 
E100 was better than PVPVA in accelerating drug release. The relative bioavailability of 
fenofibrate-Eudragit E100 1:4 (w/w) solid dispersion was 177.1% compared to 
micronized Lipanthyl capsule when tested in beagle dog [61]. 
 
Solid dispersion of nimodipine with HPMC, PVPVA and Eudragit EPO has been 
prepared using hot-melt extrusion. The dissolution results indicated that three polymers 
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are suitable carriers to enhance the in vitro dissolution rate of nimodipine in pH 4.5 
medium. XRPD and DSC data showed that drug was in amorphous form in hot-melt 
extrudates. Nimodipine was miscible with HPMC when drug loading was 10% and phase 
separation existed when drug loading was increased to 30% and 50%. The weakening and 
shift of the N-H stretching vibration of the secondary amine groups of nimodipine as 
determined by FT-IR showed hydrogen bonding between the drug and polymers in the 
solid dispersion [62]. The bioavailability study was conducted of the three solid 
dispersions in beagle dogs. The HPMC and PVP/VA dispersions exhibited much lower 
bioavailability compared to that of Eudragit EPO solid dispersion [63]. 
 
Hot-melt extrusion has attracted considerable interest within the pharmaceutical 
industry. However, how to identify the nature of the drug dispersion within the polymer 
remains a challenge. The following summary of three articles simply described the major 
techniques using for solid dispersion characterization.  
 
Sheng Qi et al developed a combined thermal, imaging and spectroscopic 
approach for the identification and characterization of the drug and polymer structure. 
DSC run at various scan rates, MDSC, microthermal analysis (mu-TA) and ATR-FTIR 
were used to characterize the solid dispersions prepared by hot-melt extrusion containing 
10% and 20% paracetamol in Eudragit E. Dispersion of the drug in the polymer on a 
molecular basis was indicated by observed single Tg. However, DSC and ATR-FTIR also 
indicated that the drug was present in both amorphous and crystalline forms 
simultaneously. The ATR-FTIR also tested that the crystalline of drug was major in the 
center of extrudate. This study indicated that a single technique may not provide enough 
required information for fully understanding the complex system [64]. 
 
The physical and viscoelastic properties of the hot-melt extrusion prepared solid 
dispersions:  indomethacin (INM) with Eudragit EPO (EPO), PVP-VA, PVPK30, and 
poloxamer 188 (P188) have been investigated by Chokshi RJ et al., A single T(g) was 
observed from the thermal analysis studies indicating good miscibility of drug and 
polymer for INM/EPO, INM/PVPVA, and INM/PVPK30 systems. In the case of 
INM/P188 solid dispersion, two melting endotherms were observed indicating partial 
miscibility of drug in polymer. Zero rate viscosity (eta(o)) and activation energy (E(a)) 
was determined for the various systems. The eta(o) of INM/EPO, INM/PVPVA, and 
INM/PVPK30 systems were found to be significantly lower as compared to pure 
polymer, indicating good miscibility of drug and polymers. INM/P188 mixtures showed a 
higher eta(o) compared to pure polymer indicating partial miscibility of drug and 
polymer. With respect to E(a), INM/EPO mixture showed an increased E(a) according to 
drug concentration increase, suggesting antiplasticization effect of the drug. The mixtures 
of INM/PVP-VA showed a decrease in the E(a) with the increasing drug concentration 
suggesting a plasticization effect of the drug. Considering these findings, a model was 
developed to correlate the zero rate viscosity to the motor load for hot-melt extrusion 
process [65]. 
 
The state of solid dispersions dissolved in dissolution media was investigated by 
Tho I et al. Ritonacir-PVPVA-Span 20 solid dispersion was prepared using hot-melt 
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extrusion. Melt extrudates with and without ritonavir were studied. Nano/micro-
dispersions formed for both drug containing and placebo system when the melt extrudate 
dissolved in dissolution media. The Nano/micro-dispersions are sensitive to anions and 
may form association, aggregation or flocculation overtime. The conclusion of such study 
was that the drug delivery system itself plays a key role for the formation of the observed 
particles [66]. 
 
Application of hot-melt extrusion method for thermo sensitive drug remains a 
challenge due to exposure to high temperatures. Three cellulose based polymers with 
relative low Tg; HPMC 3cps, HPMCP and HPMCAS were selected to prepare solid 
dispersions with a poorly water soluble drug, NVS981, which degrades upon melting at 
165 °C. Two different drug loads of 20 and 50% (w/w) were studied in each polymer 
system. Solid dispersions with 50% (w/w) drug loading were easier to process in the melt 
extruder compared to that of 20% (w/w) drug loading. High drug loading introduced 
better plasticizing effect to the system. Among the three polymers, HPMCAS was found 
to be the best one as it was easily processed and provided stable solid dispersions after 3 
months storage at accelerated stability conditions with enhanced dissolution [67].  
 
Hot melt extrusion (HME) and KinetiSol Dispersing (KSD) which is a new 
fusion-based process developed to rapidly form solid dispersions by imparting high shear 
and frictional forces were utilized to prepare solid dispersions of a BCS class II 
compound ROA with Eudragit  L100-55 and HPMCAS. The compound was chemically 
thermal sensitive and unstable in acidic pH. Since the amorphous form can’t be obtained 
by hot-melt extrusion, the KSD process was investigated to reduce the decomposition of 
ROA while rendering compositions amorphous. The results of the study demonstrated 
that KSD is an effective method of forming dissolution-enhanced amorphous solids [68]. 
 
A novel hot melt extrusion strategy has been proposed to handle thermal sensitive 
drugs. Lakshman JP et al combined spray drying and hot-melt extrusion together to 
prepare solid dispersion. The high melting point drug was first processed to get 
amorphous form using a solvent evaporation method by spray drying technique. Polymer 
and amorphous drug mixture were further processed using a hot-melt extrusion. This 
process bypassed the exposure of thermal sensitive drug to high temperature. In the hot-
melt extrusion process, the drug substance itself acted as the plasticizer for the polymer. 
Homogeneous dispersion in the matrix and subsequent enhanced dissolution of the drug 
were further improved by adding surfactant in the system. This novel system showed 
higher bioavailability than formulations containing the crystalline API. In an accelerated 
stability test, no crystalline drug was observed [69]. 
 
Although many successful commercial products of hot melt extrusion solid 
dispersion have shown the distinguished benefit of this technique, a critical prerequisite 
to the manufacturing process which is the miscibility of the drug and its carrier polymer 
is still a limitation factor for hot melt extrusion application. The drug has to be dissolved 
in the carrier polymer in the molten form, when the melt is cooling down, the drug will 
be dispersed in the carrier at molecular level.  Another limitation to the hot melt method 
is the thermostability of drug and polymer. Lower melting point of the drug-carrier 
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system is preferred. Generally, drug is more stable when it was treated at lower 
temperature. If high temperature is needed in the process, drug and carrier have to be 
thermal stable and do not decompose or evaporate. Many drug candidates are thermally 
unstable; they will be decomposed upon high temperature or the temperature near their 
melting point. In this case, an alternative method, solvent evaporation method has been 
studied and applied to make solid dispersion [70]. The major and commercial process is 
spray drying. Several commercial solid dispersion drug products are using this technique 
which has been listed in Table 2-1. The principle and technical aspects will be discussed 
in detail below. 
 
 
2.3.2 Spray drying 
 
As an alternative method for hot melt extrusion, solvent evaporation method is 
also commonly used in solid dispersion preparation. Spray drying technique has been 
widely used in food industry for milk powder production, cartridge manufacture, and 
pesticide production. In the pharmaceutical industry, it is poplar in pharmaceutical 
excipient or co-processed excipient manufacture.  
 
The basic steps for preparing solid dispersion using spray drying include:   
1. Dissolving the API, polymer carrier and any other desired adjuvants in a common 
solvent; 2. Atomising the liquid into fine droplets; 3. Rapidly removing the solvent from 
the liquid droplets as they fall through the drying chamber; 4. Collecting the resulting 
powder; and 5. Further drying the powder to remove residual solvents. 6. The final step 
was tableting or encapsulation. The Figure 2-4 showed this process.  
 
A common spray drying instrument consists of sample feeding system, heating 
unit, atomization unit and sample collection unit. The machine made by different 
manufacturer has different design [71]. The schematic diagram of a basic spray drier is 
shown in Figure 2-5. The atomization unit is the key part of a spray dryer. Commonly, 
two fluid nozzle, pressure nozzles and rotating wheel atomizers are available to meet the 
requirement of laboratory scale, pilot scale and manufacture. For laboratory application, 
two-fluid nozzle is often used. Pressure (hydraulic) nozzles are often installed for 
manufacture because it is the most efficient way in atomization. Besides, rotary atomizers 
are also available for pilot scale.  
 
 When preparing solid dispersion using spray drying, a closed system is usually 
selected since the solvent can’t be evaporated into air. The commonly used solvents 
include ethanol, acetone, ethyl acetate, tetrahydrofuran, methanol, dichloromethane, 
 
 
 
 
 
Figure 2-4. Scheme of solid dispersion preparation using spray drying technique. 
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Figure 2-5. Components of spray dryer. 
 
 
water and various combinations of these. Typical polymers include PVP, PVPVA, and 
HPMC, HPMCAS and other HPMC derivatives and acrylate copolymers. Addition of 
surfactants to stabilize the common solvent system is not uncommon [71]. The major 
advantages of spray drying technique are fast process time, the ability to work with 
thermal sensitive APIs, flexibility of process various solvent systems with various 
surfactants and polymers. After solvent is removed, the drug dispersed in the carrier 
matrix homogeneously at molecular level. In spray dried solid dispersions, particle size 
reduction, wettability enhancement and amorphous form acquisition of hydrophobic drug 
are obtained in one step. The consumption of organic solvents thus adding the costs and 
the followed requirement of residual removal are the major disadvantages of this 
technique. 
 
The properties of spray dried solid dispersion, such as density, flowability and 
residual solvent can be controlled by adjusting process parameters, such as nozzle type 
selection, inlet temperature, outlet temperature and carrier gas volume. Particle size and 
distribution decide the flowability of spray dried powder which can be optimized by 
selecting nozzle. The two-fluid nozzle usually produces small particles, the size is around 
2-30µm, larger particles are produced by pressure nozzles; the higher inlet temperature 
can shorten the whole process time and the drying time, at the same time,  residual 
solvent must be controlled at a low level. If the inlet temperature is too high, the outlet 
temperature will also be increased which may induce a sticking problem in the spray 
drying process when the outlet temperature is higher than the Tg of sample system or 
melting point of compound. However, low outlet temperature will keep more residual 
solvent in the spray dried powder which will be as plasticizer to reduce the Tg of solid 
dispersion system. Carrier gas provides heat energy to dry the sample, it can be air when 
sample has no organic solvent or can be inert gas, such as nitrogen gas when the sample 
contains organic solvent. The volume of carrier gas will affect the product yield. 
Generally, this parameter needs to be optimized according to different type of spray 
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drying instrument [71]. In summary, optimization of spray drying process is an integrated 
process; decision for each parameter will affect other parameters. Considering the final 
property of solid dispersion powder, all parameters will be optimized and decided 
together. The commercialized drug product manufactured by spray drying method was 
shown in Table 2-1. The articles of spray dried solid dispersion published in recent years 
are reviewed as follows: 
 
A ternary system: solid dispersions griseofulvin, PHPMA and PVP have been 
prepared using spray drying technique. Acetone and water or acetone and methanol were 
selected to dissolve drug and polymer. The solvent system affected the properties of solid 
dispersions significantly. Thermal analysis was done for the spray dried solid dispersion 
powders, high Tg was about 103 degrees C for the acetone/methanol system, while for 
acetone/water system, the Tg was 83 degrees C. This is because the conformational 
variations of the polymers in solution prior to spray drying. The effect of drug and 
polymer concentration on the properties of solid dispersions was also studied. A lower 
relaxation rate was found to solid dispersions which spray dried from dilute drug-polymer 
solution [72]. 
 
Caron V et al investigated the sulfathiazole (STZ)/ PVP and sulfadimidine 
(SDM)/PVP solid dispersions preared by spray dying and co-milling method. Multiple 
analysis techniques have been applied to characterize the two solid dispersions. Both 
spray drying and co-milling method can produce homogeneous glass solutions for the 
two model drugs and the value of T(g) for a particular API/PVP ratio did not depend on 
the processing technique used. According to the Gordon-Taylor equation, the interaction 
between drugs and PVP are not stong which was indicated by the consistent results of 
measured Tg and predicted Tg and the variation of T(g) versus concentration of PVP was 
monotonic for all the systems. Amorphous SDM can be obtained on spray drying but not 
amorphous STZ. Flory-Huggins model was applied to calculate the miscibility of two 
APIs and PVP. The results showed that the two APIs have similar miscibility with PVP. 
Intrinsic dissolution studies in aqueous media revealed that dissolution rates of glass 
solutions were the fastest no matter the preparation method. A conclusion was made that 
co-milling can significantly enhance the dissolution of some poorly soluble drugs to a 
similar magnitude as co-spray dried systems [73]. 
  
A review article covered how the particle formed by spray drying technique from 
theory to practice. Some application examples in pharmaceutical industry -- low density 
particles, composite particles, microencapsulation, and glass stabilization -- are 
discussed, with specific emphasis on the underlying particle formation mechanisms and 
design concepts [74]. 
 
 An application of poly(2-hydroxyethyl methacrylate) (PHEMA) hydrogel  in 
solid dispersion has been studied. Three drugs: diclofenac sodium, piroxicam and 
naproxen are selected as model drugs. XRD, DSC and FTIR are used to characterize 
these solid dispersions and stability under various conditions. The results show that as 
high as 30% drug loading is acceptable, above that will induce amorphous to crystalline 
transition. During storage, high RH% will increase the recrystallization rate duing storage 
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for any drug loading. The FTIR result indicates that hydrogen bonding presents among 
drug and polymer. Dissolution rate of the three model drugs in solid dispersion increased 
compare to their physical mixture. A conclusion has been made that the PHEMA can be 
used as potential solid dispersion carrier to enhance drug dissolution rate and futher 
bioavailability [75]. 
 
Solid dispersion piroxicam –PVP prepared by spray drying and supercritical CO2 
fluid method has been studied by Ke Wu et al. DSC, FTIR and XRPD were applied to 
characterize properties of solid dispersion. Multiple techniques showed amorphous form 
was presnt in the binary system with 20% drug loading. The dissolution rate of piroxicam 
in solid dispersion prepared by supercritical CO2 fluid increased significantly compared 
to that of API itself. From the investigation, the author drew the conclusion that PCA 
(supercritical fluid CO2) processing could be an effective alternative method to prepare 
solid dispersion [76]. 
 
In the early stage of solid dispersion research, 1970s’ to 1980s’, PEG and PVP are 
the most common polar polymers. After that, semi-synthesized polymers, such as HPMC 
or its derivatives were used and studied as solid dispersion carriers. Besides PEG and 
PVP, HPMC became the third type of polymer that was applied in commercial drug 
products. Bend research Inc. recently published an article reviewed more than one 
hundred compounds that form solid dispersion with hydroxypropyl methylcellulose 
acetate succinate (HPMCAS) by spray drying method. These spray dried dispersions 
(SDDs) kept supersaturation and amorphous drug/polymer colloids in in vitro dissolution 
determinations and were found to have large bioavailability increases in vivo. At the 
same time, those compounds can remain amorphous form during storage. This large scale 
solid dispersion test proved that the spray drying technique and HPMCAS is a successful 
combination for solid dispersion preparation [77]. 
 
 
2.3.3 Supercritical fluid extrusion 
 
Besides hot-melt extrusion and spray drying method, supercritical fluid has been 
also introduced as a solid dispersion preparation method. Supercritical fluid is neither gas 
nor liquid. However, it has the properties of gas and liquid at the same time. Under 
certain temperature and pressure, gas can form supercritical fluid which has the high 
density and low viscosity. The special fluid has the solvent capacity to extract constitutes 
from plants according to the polarity. Upon the adjustment of pressure, the supercritical 
fluid will extract material from low polarity to high polarity and then enter the separation 
unit, where supercritical fluid is separated with the extraction and then go to collection 
unit for recycle. Carbon dioxide (CO2) is the most commonly used media in supercritical 
fluid technique. In solid dispersion preparation, compound and polymer will be first 
dissolved in common solvent, then the sample is treated by CO2 supercritical fluid, 
solvent will be extracted and removed by CO2 fluid and the solid dispersion powder is 
separated and precipitated from solvent. The common solvent and CO2 will be further 
separated for recycle. The advantage of CO2 supercritical fluid method is its low cost and 
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environmental friendly, the solvent residual in solid dispersion powder is less than that of 
spray drying method. 
 
Rodier et al prepared eflucimibe-γ-cyclodextrin co-crystal solid dispersion using 
supercritical fluid extraction method. Both the solubility and the dissolution rate were 
improved. Eflucimibe and cyclodextrin have been dissolved in DMSO and then treated 
with supercritical carbon dioxide, solvent was removed. Then the co-crystal was kept 
under supercritical condition for several hours, then the solid dispersion was treated a 
second time by supercritical carbon dioxide to remove residual solvent. The three step 
operation process made efludimibe homogeneously dispersed in γ-cyclodextrin. The 
properties of solid dispersion are not sensitive to the operation parameters [78]. 
 
Won et al. have prepared felodepine solid dispersion using conventional solvent 
evaporation method, CSE and supercritical anti-solvent method, SAS. The carrier 
includes HPMC and surfactant. Felodepine is in amorphous form no matter the 
preparation method. The SAS method is better than CSE method after comparing the 
properties of the solid dispersions. The solid dispersion prepared by SAS method has 
smaller particle size, better flowability, less residual solvent, higher solubility and faster 
dissolution rate [79]. 
 
 
2.3.4 Other methods 
 
Co-grinding and electrostatic spinning method are also used to prepare solid 
dispersion [80, 81]. 
 
 
2.4 Characterization Techniques  
 
Many techniques are available to contribute information for explanation of the 
physicochemical phenomenon of solid dispersions. Generally, a combination of two or 
more techniques is required to characterize a solid dispersion system. The advantages and 
disadvantages of each technique are briefly discussed below. 
 
 
2.4.1 Powder X-ray diffraction (XRPD) 
 
XRPD is applied to determine whether crystal or amorphous form exist in solid 
dispersion, it can also quantify crystalline degree if the crystalline standard curve can be 
made [82]. X-rays are considered radiation in the electromagnetic radiation spectrum, the 
wavelength of X-rays is around 0.01 nm to 10 nm. Crystalline material has a 
characteristic atomic structure and it will diffract X-rays in a unique pattern. The 
amorphous form generally is indicated by a wide and flat peak, basically, no sharp peak 
appears in amorphous material X-ray spectrum. Based on the physical state of various 
materials, XRPD can also be used in measurement and prediction of crystal size and 
shape, protein structure characterization, etc.  
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XRPD is a straightforward method to distinguish a crystalline from an amorphous 
system. Its sensitivity is around 5%. In solid dispersion characterization, it is often 
combined with other techniques to characterize the phase separation, crystalline degree 
even the size of crystal. When determining the crystalline degree, a series standard 
sample needs to be prepared: 5 to 7 crystal concentration points are needed to construct a 
wide range standard curve with a determined limit of quantitation. Using a calibration 
curve to quantify the crystalline content is similar to that of other chemical quantify 
methods, such as HPLC. 
 
Anthony Severdia et al used XRPD to determine the content of crystalline form I 
in crystalline form II. They mixed form I and II at different ratio and then constructed 
calibration curve using peak area or peak height. When they used peak area to construct 
standard curve, the R2 was better than that of peak height, but the difference was not 
large. The author also quantified the content of form I in form II using an NIR method. 
Basically, both XRPD and NIR methods can be used in crystalline quantitive analysis, 
but when the crystal content was lower than 5%, the accuracy of measurement will be a 
problem [83]. 
 
 
2.4.2 Thermal analysis methods  
 
Thermal analysis tools are often used in solid dispersion characterization. 
Differential scanning calorimetry, DSC and thermal gravimetric analysis, TGA are most 
commonly used. DSC can measure many thermal transition phenomena including 
melting point, glass transition point, or recrystallization transition, etc. These 
measurements provide qualitative and quantitative information that about physical and 
chemical changes that involve endothermic or exothermic processes or change in heat 
capacity. Modulated temperature DSC is derived from conventional DSC. The 
temperature is continually increasing in sinusoidal modulation (oscillation) way which is 
different from the linear fashion of traditional DSC. Thermal events respond differently 
to the oscillation heating rate. In MDSC, glass transition temperature can be easily 
observed and assigned. A disadvantage of MDSC is it is time consuming: one hour or 
longer time is needed for a typical MDSC data collection [84]. 
 
TGA measures mass change of a substance as a function of temperature while the 
substance is subjected to a controlled temperature program. If the substance contains a 
volatile fraction, the mass will be lost when the temperature is high enough. TGA is also 
combined with DSC to differentiate the true melting and decomposition. If a sample has 
the melting combined decomposition, DSC can only give an endothermic melting peak or 
exothermic peak. As for the exothermic peak, it is generally assigned as a decomposition 
peak; however, to confirm this assignment and remove the possibility of operation error, 
sample is further tested by TGA. The observed weight loss curve shown in the same 
temperature range on TGA will verify the results of DSC.  
 
In nearly every published article related to solid dispersion, DSC has been applied 
as a routine tool to measure the glass transition temperature, melting point; to distinguish 
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phase separation as well as to quantify the content of crystal in glass solution system. 
Generally, phase separation will be defined when two Tgs are found in DSC, however, 
this technique has its own limitation sometimes. The Tg of separated glass domain may 
not be measured by DSC if the separated domain is just about 30 nm. Newman et al using 
XRPD coupled with computation of pair distribution functions (PDF) technique 
successfully found a 30 nm phase separation domain in indomethacin-PVP binary glass 
solution system [85].  
 
 
2.4.3 Fourier IR   
 
Fourier transform infrared spectrum is a specific character for compound. 
Commonly, the spectrum of a compound before process and after process will be 
compared to see if there is difference that can be found in the spectrum profile. The 
spectrum of crystalline and amorphous state of a compound usually reflects differences in 
FTIR. Based on this point, FTIR is applied together with other techniques to characterize 
solid dispersions. The advantages of this technique include the small sample size (about 
several micrograms), quick test time (several minutes) and relatively inexpensive and 
easy to operate. 
 
FTIR was used to study the effect of compression on miscibility of naproxen-PVP 
K25 solid dispersions. FTIR analysis showed the unchanged profile of drug in solid 
dispersion upon compression when drug loading was 20%. While, when drug loading 
was increased to 30% and 40%, phase separation was induced by compression pressure 
(565.05MPa). The altered IR spectral profile and two Tg in DSC confirmed this point 
together [86].  
 
Qi et al applied Attenuated Reflection Fourier Transform IR (ATR-FTIR) 
combined thermal and imaging technique to identify the paracetamol-Eudragit® E solid 
dispersion. Spectrum evidence obtained from FTIR indicated the presence of crystalline 
in 10% and 20% drug loading solid dispersion system and the major location of 
crystalline was in the center of the extrudate [64].   
 
 
2.4.4 Scanning differential microscopy (SEM) 
 
SEM technique is a more direct tool to investigate solid dispersions. The 
morphology of solid dispersion powders or extrudates can be easily observed visually. 
Sometimes, SEM can show if the sample is crystalline or if there is phase separation. 
However it is limited by the resolution. The very small crystalline may not be observed 
by SEM technique.  
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2.4.5 Dynamic vapor sorption (DVS) 
 
DVS is applied to determine the moisture sorption properties of pharmaceutical 
materials such as excipients, drug formulations and packaging films. These properties are 
recognized as critical factors in determining the storage, stability, processing and 
application performance of drug products [87, 88]. Further, organic solvent and water can 
be selected to study solvate or hydrate formation [89]. It can also be used as the very 
sensitive method to qualitatively and quantitatively determine amorphous contents [90].  
 
Lesley et al. apply DVS technique to determine the amorphous content in a 
micronized compound. Water and acetone are used to provide vapor pressure to construct 
the calibration curve. In the experiment, 100% amorphous and 100% crystalline states are 
characterized by a variety of techniques. Water vapor does not induce recrystallization 
but acetone vapor can induce recrystallization. The lowest quantitative limit of this DVS 
method for amorphous content determination is 0.5%. The measurement is in agreement 
with the results that are determined by DSC [90]. 
 
 
2.4.6 Solid state NMR and 2D NMR  
 
Solid-state NMR (SSNMR) can provide detailed structural information about 
amorphous solid dispersions of pharmaceutical small molecules. In contrast with solution 
state NMR, solid-state NMR (ssNMR) does not require that the sample be soluble or 
form a crystal, and no specific NMR solvent consumed. Two dimensional NMR is 
usually combined with this technique in solid dispersion characterization.  
 
In SSNMR, dipolar correlation, spin diffusion, and relaxation measurements can 
be separately applied or combined to characterize the structure of solid dispersions. 
Observation of spin diffusion effects using the 2D H1-C13 cross-polarization 
heteronuclear correlation (CP-HETCOR) can show glass solution formation. H1 
doublequantum correlation experiments to probe interaction at molecular level between 
polymer and drug. H1-F19 CP-HETCOR serves a similar role as CP-HETCOR for 
fluorinated drug molecules. The sharpness degree of peak in NMR spectrum and 
difference to its amorphous or crystal control indicate if there is glass solution formation. 
Phase separation is detected using C13, F19, and Na23-detected H1 T1 experiments, 
dipolar correlation and spin diffusion effect are observed to prove the molecular 
interaction between drug and polymer. Two more examples: solid dispersion ternary 
system of voriconazole and telithromycin with PVP and SLS are analyzed to demonstrate 
the general applicability of the technique [91]. 
 
Lefort et al determines the amorphous content of trehalose in mixture of 
amorphous and crystal trehalose using SSNMR. The results of C13NMR method is 
compared to that of DSC technique. The good agreement of the two methods indicates 
that both are useful and accurate methods for compositional characterization of powders 
[92]. 
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2.5 Conclusion 
 
The review summarizes several aspects of solid dispersion: concept definition, 
background, commercial products, solubilization mechanisms, preparation methods, 
characterization techniques. Solid dispersion is shown to be a fruitful approach to 
increase the bioavailability of poorly soluble drugs because of increasing number of drug 
candidates with low solubility. In addition to binary solid dispersion systems, researchers 
also add surfactant or cyclodextrin in drug-polymer system to form ternary solid 
dispersion for better drug performance. It has been a common strategy for poorly soluble 
drug development.   
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CHAPTER 3.    AQUEOUS SOLUBILITY, DISSOLUTION, 
PHYSICOCHEMICAL CHARACTERIZATION AND PHYSICAL 
STABILITY OF SOLID DISPERSIONS OF FUROSEMIDE AND OCTENYL 
SUCCINIC ANHYDRATE STARCH 
 
 
The purpose of the present study was to investigate the applicabability of a cold 
water soluble modified starch, octenyl succinic anhydrate starch (OSA starch) as solid 
dispersion carrier to increase the aqueous solubility and dissolution rate of poorly water 
soluble drug. Furosemide was selected as a model drug. The solid dispersion of 
furosemide with OSA starch was prepared using spray drying technique via various 
sample preparation methods: furosemide dissolved in ammonia solution (salt control), 
furosemide and OSA starch dissolved in ammonia solution (amorphous dispersion,) and 
furosemide dispersed in OSA starch solution (crystal dispersion). Physical mixtures (PM) 
were also prepared for comparison. Three ratios between drug and OSA starch: 1:1, 1:2.3 
and 1:9 w/w were selected and tested. The pH of solid dispersions, aqueous solubility and 
dissolution (under pH1.2 and pH 5.8) of the drug in these solid dispersions were 
evaluated compared to drug physical mixtures. Furthermore, their physicochemical 
properties were investigated using SEM, FTIR, MDSC, XRPD and Dynamic vapor 
sorption (DVS). Physical stability tests were done under 40 °C and 40 °C with 75% RH 
for 3 months, furosemide kept its amorphous form in all samples at 40 °C, while 
crystallization was found in samples treated under 40 °C 75% RH conditions. The 
solubility improvement of samples was significant and in the order of: amorphous 
dispersion > salt control > crystal dispersion = PM. Tablets were compressed for 
dissolution test. In phosphate buffer (pH 5.8), drug released near completely in 20 
minutes for all samples except PM (1:1 drug: polymer w/w). In simulated gastric fluid 
(SGF, pH 1.2), the drug dissolution was tested for one hour and the  dissolution rate was 
as the rank of: amorphous dispersion (1:9 w/w drug: polymer) > crystal dispersion 
(1:1>1:2.3>1:9 w/w drug: polymer) > PM (1:9>1:2.3 w/w drug: polymer) > amorphous 
dispersion (1:2.3 w/w drug: polymer) > PM (1:1 w/w drug: polymer) > Lasix® > 
amorphous dispersion (1:1 w/w drug: polymer) > salt control. At the 60 minute point, 
only amorphous dispersion (1:9 w/w drug: polymer) released 80% API and the highest 
amount of drug released was 65% for other samples. Using a high amount of OSA starch 
in amorphous dispersions to keep a supersaturation state of furosemide in acidic 
conditions was thought to be the principle factor for dissolution improvement. From the 
study, OSA starch can be applied as a solid dispersion carrier with controlled humidity. 
Both the preparation method and starch amount play critical role in developing a binary 
solid dispersion system for a poor water soluble drug.    
 
 
3.1 Introduction 
 
Solid dispersion is one of the drug solubilization techniques that is utilized to 
formulate poorly water-soluble drugs. It is a well-established method that has 
successfully brought several poorly soluble drugs to market, e.g. telaprevir, etravirin and 
verapamil, etc. The major preparation method includes melting and solvent-evaporation 
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method [93]. Basically, drug and polymer mixture is heated until it melts and then 
quenched cool to get solid dispersions or dissolve drug and polymer in a common solvent 
and then spray drying the solvent to get solid dispersion. Moreover, another method: 
surface-attached solid dispersion has been developed to avoid using organic solvent. 
Drug is dispersed in polymer water solution and remains in crystal form with small 
particle size upon evaporation of water [94]. This solid dispersion could increase 
solubility and bioavailability of drug and at the same time, however not change its 
crystalline state. The major mechanisms of solid dispersion techniques contribute include 
one or more of the following: enhanced water wettability, particle size reduction, reduced 
aggregation and agglomeration and enabling creation of an amorphous state [42, 43].  
 
OSA starch is made by esterification of already hydrolyzed and depolymerized 
starch and anhydrous octenylsuccinic acid under alkaline conditions [95]. OSA treated 
starches contain hydrophobic octenyl side chains which impart an emulsifying capability 
to the starches. Thus, the OSA starch bears an amphiphilic property that has been widely 
used for many years for flavor encapsulation and emulsifier for beverage emulsions. It 
has good cold water solubility, low viscosity of solution at high solid content, non-
hygroscopic character, bland taste, non-reactivity and low cost. All these advantages 
make it a good spray drying carrier material [96].  
 
When OSA starch is used in solid dispersions via spray drying technique, the 
hypothesis is that the drug dissolved in starch solution. When water evaporates via spray 
drying, the drug will be solidified together with starch and mostly the drug is in 
amorphous form because the very fast spray drying process (seconds) prevents drug 
crystallization. In the spray dried powder, the drug won’t be distinguished from the starch 
matrix. In this system, starch is homogenously distributed in the matrix thus prevents 
drug crystalline growth. When drug is dispersed in starch solution, starch will encapsulate 
drug particles to complete the microencapsulation process. Micro-scale drug particles 
will be retained in the starch matrix. These properties will be helpful in enhancing drug 
solubility and dissolution rate.   
 
Furosemide is a loop diuretic that acts on the kidney to remove excess water and 
electrolytes into urine, thus reducing the body fluids. Furosemide was used to treat 
hypertension, congestive heart failure and edema [97]. Furosemide is a BCS class IV 
drug. It is often selected as model drug to test new formulation techniques or as candidate 
for drug optimization because of its low and various bioavailabilities [97, 98]. Many oral 
formulations have been used in order to increase solubility of furosemide such as 
cyclodextrin complexes [99-101], dendrimer complexes [102], self micro-emulsifying 
drug delivery systems [103], mesoporous silicon microparticles [104], solid dispersion 
with various carriers [105-108] have been investigated. 
 
The purpose of present study is to explore the applicabability of OSA starch as 
solid dispersion carrier in the pharmaceutical field. Since it is a good spray drying agent, 
spray drying technique is one of the major methods for solid dispersion preparation, and 
because of its amphiphilic property, OSA starch is theoretically considered as a solid 
dispersion carrier. Thus, experiments are conducted to evaluate the effect of OSA starch, 
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preparation method on the solubility, crystalline and dissolution of model drug in solid 
dispersions. Solid dispersions containing furosemide were prepared as salt control, 
amorphous dispersions and crystal dispersions. Solubility and dissolution were 
determined for these solid dispersions. Multiple techniques have been applied to 
investigate their physicochemical properties and solubilization mechanisms. Accelerated 
stability test was conducted at 40 °C, controlled humidity and 40 °C, 75% RH for three 
months to fully evaluate the quality of solid dispersion.  
 
 
3.2 Material and Methods 
 
 
3.2.1 Material 
 
Furosemide was generously donated by Teva Pharmaceuticals (Petah Tikva, 
Israel), OSA starch was provided by National Starch & Chemical (Bridgewater, NJ). 
Ammonia aqueous solution was 29.4%. All other chemicals were reagent grade and used 
as received without further processing. 
 
 
3.2.2 Preparation of furosemide-loaded solid dispersions 
 
A Büchi 290 mini spray dryer with 0.7mm nozzle (Flawil, Switzerland) was used 
for the preparation of the furosemide-loaded solid dispersions. Since furosemide was 
weak acid with pKa 3.8, its solubility is pH dependent. Ammonia solution was used to 
dissolve certain amount of furosemide. All liquid samples were delivered to the nozzle at 
a flow rate of 5 mL/min via a peristaltic pump and spray-dried at 120 °C inlet 
temperature and 65–70 °C outlet temperature. The Q-flow was 45-50 mm and the 
aspirator was set as 90-100%. 
 
 
3.2.2.1 Salt control preparation 
 
A certain amount of furosemide (2g) dissolved in 65 mL ammonia water: the 
molar ratios between furosemide and ammonia were 1:1.4 (I), 1:3.6 (II), 1:6.0 (III) and 
1:17.9 (IV). The ratio 1:1.4 was the minimum molar ratio to dissolve furosemide in 
aqueous ammonia. Then these aqueous solutions were spray dried to get ammonia salt 
control samples. These salt solid dispersions were vacuum dried overnight to remove 
residual ammonia and then store in refrigerator for fully characterization. By aid of a 
basic environment that ammonia provided, furosemide and OSA starch can be easily 
dissolved in water at the same time. This is the critical step for solid dispersion 
preparation using solvent-evaporation method. 
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3.2.2.2 Solution solid dispersion preparation (Soln. SD) 
 
Three ratios (1:1, 1:2.3 and 1:9 w/w) between furosemide and OSA starch were 
selected to prepare amorphous solid dispersions. Ammonia solution (29.4%) 0.5 ml was 
added to 35 ml water, then 1 g furosemide was added into ammonia solution, then OSA 
starch 1 g, 2.3 g and 9 g were added to the furosemide ammonia solution separately. In all 
amorphous dispersion samples, the ratio between furosemide and ammonia was 1:1.4 
(mol/mol). After stirring and mixing well, these colloid solutions were spray dried to get 
powder. These solid dispersion powders were stored at refrigerator for characterization 
after drying in vacuum oven overnight.   
 
 
3.2.2.3 Suspension solid dispersion preparation (Susp. SD) 
 
OSA starch 1 g, 2.3 g and 9 g dissolved in 35 ml water, and then 1 g furosemide 
was added into starch solution, less than 5% PEG 400 was added into the liquid as 
dispersion stabilizer to prevent precipitation during spray drying process. Then the liquid 
was converted to powders after spray drying. Then the same process step was applied for 
the powder as former samples.   
 
 
3.2.2.4 Physical mixture (PM) 
 
OSA starch 1 g, 2.3 g and 9 g were mixing with same amount of furosemide using 
liquid-solids blender (type: LB-4455, The Patterson-Kelley Co, east Stroudsburg, PA.) 
for 3 min each. Then store in regenerator for further characterization.  
 
 
3.2.3 Aqueous solubility measurements 
 
Excess amounts of furosemide (about 10 mg) for salt control, amorphous 
dispersion, crystal dispersion powders and physical mixtures were added into triplicate 20 
ml screw-capped vial that contained 10 ml R.O. water (pH 6.2). The vials were vortexed 
for 30 seconds at 1000 rpm, and then put on a shaker, shaking at room temperature (25 
°C ± 1 °C) for 24h, centrifuged at 3000×g for 10 min (Eppendorf, NY), filtered through 
a membrane filter (0.22 µm) and then diluted to proper concentration for analysis by 
HPLC. The HPLC system was a HP 1100 system together with a Nova-Pak® C18 
Column (Waters, 4 μm, 150 mm Χ 3.9 mm, i.d.) and a UV Detector. The mobile phase 
was 10 mM potassium phosphate monobasic and methanol (60/40, v/v), pH adjusted to 
2.5 by phosphoric acid. The flow rate was 1 ml/min, injection volume was 10 µl and the 
wavelength was 276 nm. 
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3.2.4 pH measurements 
 
After spray drying and vacuum oven drying, free ammonia should be removed 
from samples because of the low partial pressure of ammonia. For API, salt control, solid 
dispersion and physical mixture, a 1% dispersion (w/v) was prepared in triplicate for pH 
measurement to determine the effect of pH on solubility of the solid dispersions. The pH 
of liquid samples before spray drying was also measured.  
 
 
3.2.5 Shape and surface morphology 
 
The photomicrographs of furosemide, OSA starch, solid dispersion powders and 
physical mixture were obtained by environmental scanning electron microscope (SEM) 
with backscattered electron detector (QUANTA™, FEI, Hillsboro, OR). Powders 
were mounted on a double faced adhesive carbon tape; then low vacuum (50 and 80 Pa) 
was applied in the chamber, allowing us to observe the powders without further 
treatment. The voltage was 10kV, working distance was 10 to 8 mm, spot size was 3 and 
the magnification was from 250X to 5000X. 
 
 
3.2.6 Crystallinity, thermal and spectroscopic properties  
 
The crystallinity of the API, OSA starch, physical mixture and solid dispersions 
were assessed by X-ray powder diffraction (XRPD). The experiment was conducted at 
ambient temperature using monochromatic Cu K radiation at 40mA and 40kV in the 
range of 5°  2θ  30° with an angular rate 0.02° / s. Thermal properties of these samples 
were obtained by a differential scanning calorimeter with modulated temperature (DSC 
Q2000, TA Instruments, DE). The samples of around 5 mg were placed in aluminum 
pans and were tested by a modulated temperature DSC program: equilibrated at 30 °C, 
scanning from 30 to 250 °C with a heating rate of 2 °C /min, a period of 60 s and 
amplitude of ±0.32 °C. Fourier transform-infrared spectra were obtained on a FT-IR 
spectrometer (Perkin Elmer, Waltham, MA). The sample powder was measured directly 
with no additional preparation.  
 
 
3.2.7 Humidity effect on solid dispersion and Dynamic Vapor Sorption (DVS)  
 
DVS experiment was conducted to characterize if there is humidity induced 
crystallization and hygroscopicity of samples. The experiments were undertaken using a 
Dynamic Vapor Sorption apparatus (DVS, Surface Measurement Systems, London, UK). 
The instrument has a microbalance inside a temperature-controlled cabinet. Temperature 
was kept at 25 °C for all experiments with dry nitrogen gas purge at 200 ml/min. The rate 
and extent of water uptake determined over a range of 0 to 90 to 0% RH cycle. The 
equilibrium was assumed when the weight change was less than 0.02% w/w. The time for 
each sample varied from 5-10 hrs.  
 
 43 
For control I, one more DVS experiment was done to demonstrate humidity 
induced recrystallization from a amorphous furosemide salt. The sample was treated 
under dry condition (0%RH) for 1h, and then was treated with constant moisture 
(75%RH) under isothermal (25 °C) environment for 5 hrs. Then the sample was collected 
to run MDSC or DVS with a fixed relative humidity (75% RH for salt control I). 
 
 
3.2.8 Physical stability 
 
Solid dispersion physical stability was performed at 40 °C for 3 months, at 40 °C/ 
75% RH for 2.5months and ambient condition (25 ±5 °C, 25-55%RH) for 4 months. 
XRPD was performed as 2.6 to observe if crystal grew in these samples.  
 
 
3.2.9 Dissolution 
 
Simulated gastric fluid (pH 1.2) and phosphate buffer (pH 5.8) were prepared for 
dissolution tests. The experiments were conducted at 37 °C using the USP II method with 
100 rpm paddle stirring speed and medium volume of 900 or 600 ml. Solid dispersions 
equivalent to 20 mg furosemide plus other excipients were compressed into tablets using 
Carver press (Wabash, IN). Tablet weight and formulation ingredients were shown in 
Table 3-1. Compression force was 1.1 mTon; dwelling time was 3 seconds. The punch 
size was 3/8 inch. The percentage drug release was monitored using an on-line UV-Fiber 
optic dissolution system (Dynamic Dissolution Monitor™ system, Woodbridge Scientific 
LLC, CT). 
 
 
Table 3-1. Ingredients of two tablet formulations. 
 
Formulation  I  %  Formulation II  % 
Solid dispersion powder 64.5 Solid dispersion powder 64.5 
Starch 1500 32 MCC  27 
Ai-Di-Sol 3 Ai-Di-Sol 3 
MgSt  0.5 MgSt  0.5 
Colloid silicon dioxide  5 
Tablet weight: 35mg, salt control I, 65mg, corresponding to solid dispersion (50% drug   
loading), 105mg, corresponding to solid dispersion (30% drug loading), 310mg, 
corresponding to solid dispersion (10% drug loading).  
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3.3 Results and Discussion 
 
 
3.3.1 Aqueous solubility and 1% dispersion pH 
 
Aqueous solubility of all samples was shown in Figures 3-1, 3-2 and 3-3. In each 
figure, the solubility of API was also shown. The summary of all the solubility and pH of 
1% dispersion (w/v) was shown in Table 3-2. For salt control samples, four molar ratios 
between furosemide and ammonia were screened to select a proper ratio that can increase 
the solubility of API to the highest degree. Ammonia acted as a base toward water to 
form a mixture of the ammonium and hydroxide ions. Then the oxygen of furosemide 
will combine ammonium ions to form salt. The reaction can be representing as  
Figure 3-4.  
 
Theoretically, the reaction of furosemide and ammonia was in 1:1 molar ratio. But 
practically, the molar ratio 1:1.4 was the minimum amount of ammonia needed to 
dissolve furosemide. When amount of ammonia increased, the solubility increased, too. 
However, the solubility did not continually increase when the molar ratio increased from 
1:6 to 1:17.9. The molar ratio that can enhance solubility most should be in the range of 
1:1.4 to 1:6.0. From the present results, the molar ratio 1:3.6 was the best one. This 
phenomenon can be explained as: at a proper ratio, furosemide formed salt with 
ammonium in solution and after spray drying process, the excess amount of free 
ammonia will be removed. However, the purpose of the present study was to test the 
effect of OSA starch on solid dispersion, so the molar ratio 1:1.4 was selected to prepare 
solid dispersion samples. The pH of 1% furosemide dispersion was about 4.8, the pH of 
1% dispersion of spray dried salt control samples increased at least one unit and solubility 
increased about 11 to 48 fold. The salt form contributed to enhanced solubility, and 
additional discussion of the control samples will be shown later. 
 
 
 
 
Figure 3-1. Aqueous solubility of controls.  
S0: aqueous solubility of furosemide, CI: salt control I, API: ammonia 1:1.4 (mol/mol); 
CII: salt control II, API: ammonia 1:3.6 (mol/mol); salt control III, API: ammonia 1:6.0 
(mol/mol); salt control IV, API: ammonia 1:6.0 (mol/mol). Each value represents the 
mean±SD (n = 3). * Each pair, P<0.05, student’s t test.  
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Figure 3-2. Aqueous solubility of amorphous solid dispersions.  
S0: aqueous solubility of furosemide; CI: salt control I, API: ammonia 1:1.4 (mol/mol); 
CII: salt control II, API: ammonia 1:3.6 (mol/mol); 1:1, amorphous solid dispersion 
API:OSA starch=1:1 (w/w); 1:2.3, amorphous solid dispersion API:OSA starch=1:2.3 
(w/w), 1:9, amorphous solid dispersion API:OSA starch=1:9 (w/w). Each value 
represents the mean±SD (n = 3). * Each pair student’s t test, P<0.05 except samples 1:1 
and 1:2.3. ** No significant difference between samples: 1:1 and 1:2.3.  
 
 
 
 
 
 
Figure 3-3. Aqueous solubility of suspension solid dispersions and physical 
mixtures. 
S0: aqueous solubility of furosemide; Susp. SD 1:1, spray dried suspension solid 
dispersion, API: OSA starch=1:1 (w/w); Susp. SD 1:2.3, spray dried suspension solid 
dispersion, API: OSA starch=1:2.3 (w/w); Susp. SD 1:9, spray dried suspension solid 
dispersion, API: OSA starch=1:9 (w/w); PM 1:1, physical mixture, API: OSA starch=1:1 
(w/w); PM 1:2.3, physical mixture, API: OSA starch=1:2.3 (w/w); PM 1:9, physical 
mixture, API: OSA starch=1:9 (w/w). Each value represents the mean±SD (n = 3). 
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Table 3-2. Summary of aqueous solubility and pH of 1% dispersion (w/v). 
 
Samples pH Aqueous solubility (mg/ml) mean ± SD 
API 4.84 0.096 ± 0.77 
OSA starch 4 NA 
Control I 6.3 1.4 
Control II 6.82 4.6 
Control III 6.6 3.2 
Control IV 5.96 1.1 
Soln. SD 1:1 6.24 7.8 
Soln. SD 1:2.3 6.06 8.2 
Soln. SD 1:9 5.95 19.2 
Susp. SD 1:1 4.56 0.051±3.9 
Susp. SD 1:2.3 4.34 0.034±1.7 
Susp. SD 1:9 4.15 0.033±3.3 
PM 1:1 4.42 0.034±0.87 
PM 1:2.3 4.32 0.029±3.9 
PM 1:9 4.2 0.032±2.4 
 
 
 
 
 
 
Figure 3-4. Scheme of reaction between furosemide and aqueous ammonia. 
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For solution solid dispersion samples, furosemide solubility was increased from 
0.096 mg/ml, 1.4 mg/ml (CI) to 19.2 mg/ml (1:9). Since OSA starch was acidic, the pHs 
of solid dispersions were lower than their salt control counterpart. The enhanced 
solubility did not contribute to pH increase. Amorphous salt formation should be the 
major contributor which will be further verified in following discussion.  
 
For suspension solid dispersion and physical mixture, since OSA starch was 
acidic and furosemide was weak acid, the equilibrium solubility of suspension solid 
dispersions and physical mixture powders was similar or a little bit lower than that of 
furosemide. The spray drying process didn’t alter the solubility of suspension solid 
dispersion. 
 
 
3.3.2 Shape and surface morphology 
 
The photomicrographs of furosemide, OSA starch, solid dispersion powders and 
physical mixture were shown in Figures 3-5 and 3-6. The SEM picture gave the most 
direct way to show surface morphology and shape of spray dried powders.  
 
The furosemide is a crystallized powder, composed of very small crystals. 
OSA starch appears as an amorphous spray dried powder. 
 
For the salt control samples: no crystals were found in control I; the two lower 
ratios (control II and III) powders are composed of small spheres among which we find 
occasionally a ball that has crystals. For the control IV at low magnification aspect of the 
powder appears to be identical to the previous (picture didn’t illustrate) but with high 
magnification we see that all the balls are made of crystals. 
 
Solution solid dispersions: For this series, it is hard to differentiate furosemide 
and starch. Compared to the control, all solid dispersion samples appeared sphere shape 
and no furosemide crystals were found in those powders.  
 
Suspension solid dispersion: For a ratio of 1:1, a suspension of furosemide in a 
starch solution allows to obtain an agglomerated powder. Both products are well mixed. 
The crystals of furosemide are embedded in the starch matrix. When the ratio increase the 
dispersion of the crystals is not as good as before. Some particles, usually larger, contain 
a lot of crystals, others consist only of starch. 
 
Physical mixture: The crystals of furosemide and the balls of starch are well 
separated.  
 
 
3.3.3 Crystallinity (XRPD) and spectroscopic properties (FTIR)  
 
The XRPD spectrum of furosemide, OSA starch, solid dispersion powders and 
physical mixture were shown in Figure 3-7 and Figure 3-8.  
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Figure 3-5. SEM pictures (part I) of furosemide powder and OSA starch. 
Control I: salt control with furosemide to aqueous ammonia in molar ratio 1:1.4 
(10000×), Control II: salt control with furosemide to aqueous ammonia in molar ratio 
1:3.6 (5000×), Control III: salt control with furosemide to aqueous ammonia in molar 
ratio 1:6.0 (10000×), Control IV: salt control with furosemide to aqueous ammonia in 
molar ratio 1:17.9 (5000×). All controls were solid dispersion of ammonium salts of 
furosemide.  
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Figure 3-6. SEM pictures (part II) of amorphous solid dispersion with furosemide 
to OSA starch at different ratio. 
1:1, amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w) (10000×); 
1:2.3, amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w) (5000×); 
1:9, amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w) (5000×); 
Susp 1:1, crystal dispersion with furosemide to OSA starch = 1:1 (w/w) (1000×); 
Susp 1:2.3, crystal dispersion with furosemide to OSA starch = 1:2.3 (w/w) (1000×); 
Susp 1:9, crystal dispersion with furosemide to OSA starch = 1:9 (w/w) (1000×); 
PM 1:1, physical mixture with furosemide to OSA starch = 1:1 (w/w) (1000×).  
 50 
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Figure 3-6. (Continued). 
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Figure 3-7. XRPD spectrum (part I) of furosemide powder and OSA Starch. 
Control I: salt control with furosemide to aqueous ammonia in molar ratio 1:1.4, Control 
II: salt control with furosemide to aqueous ammonia in molar ratio 1:3.6 , Control III: salt 
control with furosemide to aqueous ammonia in molar ratio 1:6.0 , Control IV: salt 
control with furosemide to aqueous ammonia in molar ratio 1:17.9. All controls were 
solid dispersion of ammonium salts of furosemide. 
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Figure 3-8. XRPD spectrum (part II) of amorphous solid dispersion with 
furosemide to OSA starch at different ratio. 
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w); 
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w); 
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w); 
Susp. SD 1:1 crystal dispersion with furosemide to OSA starch = 1:1 (w/w);  
Susp. SD 1:2.3 crystal dispersion with furosemide to OSA starch = 1:2.3 (w/w);  
Susp. SD 1:9 crystal dispersion with furosemide to OSA starch = 1:9 (w/w);  
PM 1:1 physical mixture with furosemide to OSA starch = 1:1 (w/w);  
PM 1:2.3 physical mixture with furosemide to OSA starch = 1:2.3 (w/w);  
PM 1:9 physical mixture with furosemide to OSA starch = 1:9 (w/w). 
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Figure 3-8. (Continued). 
 
 
Furosemide was crystalline and many sharp peaks are shown in Figure 3-7. The 
near rectangle shape crystal of furosemide was also shown in the SEM picture. OSA 
starch basically was an amorphous polymer and no sharp peaks shown in its XRPD 
spectrum. For the four controls, they are amorphous and crystal salts. Control I and II 
were amorphous salts, the ratio between aqueous ammonia and furosemide was 1:1.4 
(mol/mol) or 1:3.6 (mol/mol). As for control III and IV samples, excess amount of 
ammonia was added to react with API which was favorable to form pure salt and 
crystallized in days.  
 
Solution solid dispersions: For this series, all the solid dispersion was amorphous 
and no sharp peaks shown on their XRPD spectrum (Figure 3-8). The ratio between 
furosemide and starch was 1:1 (w/w), 1:2.3 (w/w) and 1:9 (w/w). For all the three 
samples, the ratio between furosemide and aqueous ammonia was 1:1.4 (mol/mol).  
 
Suspension solid dispersion: a suspension of furosemide in OSA starch solution 
allows a liquid dispersion to be obtained. After spray drying the liquid suspension, 
furosemide didn’t change its crystal form. The specific XRPD spectrum of crystalline 
furosemide is shown in Figure 3-8. Increasing the starch amount didn’t affect furosemide 
changing form from crystal to amorphous.   
 
 Physical mixture: furosemide kept its crystalline form in physical mixtures no 
matter how much OSA starch added into their mixture. 
 
The FTIR spectrums were shown in Figures 3-9 to 3-12. The characteristic 
absorption bands of furosemide were C=O stretching of carboxylic acid group at 1670 
cm-1; N-H bending at 1591 cm-1, 1561cm-1; S=O stretching of the sulfonamide group at 
1318 cm-1 (asymmetric) and 1140 cm-1 (symmetric); 3350cm-1 was assigned to the NH 
stretching vibration of Ar–NHCH2 and the 3282 cm−1 band to the stretching vibration of 
SO2NH2 [109].  
 
The amorphous information also showed on FTIR spectrum. In the amorphous 
sample control I and II, even in control III which was less amorphous than that of control 
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Figure 3-9. FTIR spectrum of furosemide, OSA starch and four controls. 
 
 
 
 57 
 
 
 
Figure 3-10. FTIR spectrum of furosemide, OSA starch and solution solid   
dispersions. 
*Hydrogen bonding; **Amorphous spectrum. 
 
*
**
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Figure 3-11. FTIR spectrum of furosemide, OSA starch and suspension solid  
dispersions. 
The three solid dispersions were spray dried furosemide-OAS starch suspensions. 
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Figure 3-12. FTIR spectrum of furosemide, OSA starch and physical mixtures. 
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I and II, the bands at 3399, 3350 and 3282 became a one wide band; at the same time, 
band at 1140 cm-1 shifted to 1154-1155 cm-1and become wider; band at 1318 cm-1 
shifted to 1306-1312 cm-1 and become wide, while in the crystal control IV, all above 
mentioned bands do not have shift. One of the reasons for peak shift was that the atoms 
arrangements in amorphous samples were loose and easily affected by surrounding 
chemical environment.     
 
Solution solid dispersions: the FTIR spectrum of this series was shown in Figure 
3-9. The specific amorphous spectrum was also shown in Furo-starch Soln.1:1; Furo-
starch Soln. 1:2.3 and Furo-starch Soln. 1:9. Band at 1140 cm-1 shifted to 1147-1154 cm-
1and become wider; band at 1318 cm-1 shifted to 1307-1309 cm-1 and become wider. 
The solid dispersion of furosemide-starch yielded band shifted from 1670 cm-1 to 1605 or 
1606 cm-1 for C=O stretching of carboxylic acid group. It can be interpreted as hydrogen 
bonding between C=O group in furosemide and –OH group in OSA starch [102].   
 
Suspension solid dispersion: the FTIR spectrum of this series was shown in 
Figure 3-10. In furosemide-OSA starch 1:1and 1:2.3 samples, C=O stretching of 
carboxylic acid group at 1670 cm-1, S=O stretching of the sulfonamide group at 1318 
cm-1 (asymmetric) and 1140 cm-1 (symmetric) kept its original position. Furosemide 
kept its crystalline properties in FTIR spectrum.  
 
 Physical mixture: FTIR spectrum of furosemide kept its crystal properties in 
physical mixtures no matter how much OSA starch added 
 
 
3.3.4 Thermal analysis 
 
DSC technique was widely used in determining melting point of crystal line 
compounds. When compounds changed form from crystal to amorphous, its melting 
point will disappear and at the same time, glass transition temperature will display. The 
temperature modulated DSC (MDSC) can be very efficiently used in the case when the 
thermodynamically reversible and irreversible processes are to be distinguished. The 
glass transition was the most frequently studied example, both experimentally and 
theoretically [110, 111]. The MDSC spectrum of control I was shown in Figure 3-13.  
 
The upper one showed the Tg of amorphous control I sample and the lower one 
showed the Tg of control I which has recrystallized under high moisture condition 
(Sample was treated as method 2.7).  For the amorphous control I, its Tg was 92.33 °C 
one the reverse heat flow with heat capacity 0.3015 J/(g °C), after Tg, a thermal induced 
recrystallization peak was shown on the nonreversible heat flow which further verified 
that high amount amorphous content in control I; for humidity induced recrystallized 
control I, its Tg was 103.59 °C with heat capacity 0.1186 J/(g °C) and no recrystallization 
peak showed on its non-reversible heat flow. This point also indicated that less 
amorphous content in humidity treated control I didn’t induced a measurable 
recrystallization peak.  Calculated the difference of heat capacity, amorphous content of 
control I decreased to 38.7% comparing to that of untreated one (assuming 100%  
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Figure 3-13. MDSC of control I (before and after treated with moisture). 
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amorphous content) [112]. Data was shown in Table 3-3. The peak around 216 °C was 
furosemide melting combined with decomposition [100].   
 
For the other three control samples, their MDSC were shown in Figure 3-14. On 
the reverse heat flow spectrum of control II, a clear Tg peak showed and followed this Tg 
peak, a clear cold recrystallization peak showed at 114-140 °C. Both the symptoms gave 
strong evidence of an amorphous part in this sample. This result also correlated with 
those of XRPD and FTIR.  As for the control III sample, a very weak Tg peak integrated 
on the spectrum and no cold crystallization peak can find; similarly, no Tg and 
crystallization peak can be found in control IV. The MDSC results were in good 
agreement with those of XRPD. The crystal degree is Control I < Control II < Control III 
<Control IV. And this point can be showed visually by SEM picture.  
 
For solid dispersions, Tg of each sample was shown in Figure 3-15.Generally, 
when people make solid dispersion, the high Tg polymer will be considered since it can 
increase Tg of API. If Tg of solid dispersion is 50 °C lower than that of API, the 
amorphous form can be stable theoretically [113]. But sometimes, the pure amorphous 
form can still crystallized even in very low temperature. So forming solid dispersions 
with high Tg polymer can stabilize amorphous state and prevent crystallization [44]. For 
control I, its Tg was 92 °C, while when forming solid dispersion with OSA starch, the Tg 
was increased to 104, 108 and 116 °C separately for the ratio between furosemide and 
OSA starch 1:1, 1:2.3 and 1:9 (w/w). Amorphous furosemide should be more stable when 
it was in solid dispersion, the results of physical stability also prove this point, and this 
will be further discussed in 3.6.    
 
 
3.3.5 Humidity induced crystallization and DVS 
 
 For solid dispersions, one critical issue is to keep drug substance in its amorphous 
form. But this high energy metastable system is actively prone to rearrange itself to low 
energy and stable systems: crystal. Moisture and heat are two major induce factors to be 
considered in this transition. So, in our project, we selected thermal analysis and dynamic 
vapor sorption analysis to test those amorphous systems. Thermal analysis has been 
discussed in 3.4, we will focus on effect of humidity on solid dispersion. 
 
 OSA starch is hydrophilic material, and at high RH%, the material absorbed more 
water vapor. From 0- 50 RH%, some water were entrapped in the starch; from 50 to 90 
RH%, much more water absorbed. By the end of the experiment, 7.6% bulk water can’t 
be removed and remained in the sample. For furosemide, which is very hydrophobic 
material, little water was absorbed, even at RH% 90%, the mass increased only 0.14%. 
The isothermal DVS plot was shown in Figure 3-16. 
 
In this DVS experiment, we treat the amorphous sample with relative humidity 
range 0 to 90%. A sharp peak in 60% to 80%RH range showed in Figure 3-17. Upon 
60% RH, the amorphous part absorb moisture significantly, the mass gain from 60% RH 
to 70%RH reached 3.1% and at the same time the sample started to crystallize, then water 
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Table 3-3. Tg and heat capacity (Cp) of control I (before and after treated with 
moisture). 
 
Control I Tg onset Tg Tg end Cp Amorphous content 
Before DVS 90.22 92.33 94.43 0.3015 100%(theoretical) 
After DVS 92.58 103.59 114.06 0.1186 ~38.7% 
 
 
 
 
 
 
Figure 3-14. MDSC spectrum of control II, III and IV. 
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Figure 3-15. Tg of OSA starch, amorphous solid dispersion 1:1, 1:2.3 and 1:9. 
 
 
 
 
 
 
Figure 3-16. DVS plot of OSA starch and furosemide. 
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Figure 3-17. Water vapor sorption and desorption graph of control I. 
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was eliminated by the crystal as it formed a tight lattice, and the mass decreased sharply. 
Then the material absorbs moisture gradually until mass reached equilibrium at 90% RH. 
In desorption cycle, sample was dried little by little, then reached to -0.7% which can be 
interpreted as water in original sample was removed. Since the pH of control I didn’t 
change (Table 3-4), this weight loss should not be the ammonia. 
 
When treated amorphous control I under 0% RH for 1 hour, then under 75% RH 
for 4 hours, the mass change instantly upon moisture reached to 75%RH, the mass 
increased around 90mins, then it become flat. In about one and half hour the moisture 
induced crystallization finished.  Then the sample was collected to run MDSC, results has 
been discussed in 3.3.4. 
 
 The effect of moisture on solution solid dispersions was shown in Figure 3-18. 
The hygroscopicity of these samples was similar in the relative humidity range of 0-40%. 
The Low %RH values resulted in low vapor sorption and about 2.8% weight gain to these 
samples. In the relative humidity range of 40 to 90%, solid dispersion started to absorb 
water into bulk, weight gain reached to 23, 30, 40% for 1:1, 1:2.3 and 1:9 samples 
separately. In desorption cycle, the absorbed water can’t be removed completely and 
residual water remained in each sample. This order was highly in accordance to the starch 
amount in the samples: the higher starch content, the higher water uptake. The water 
uptake was higher than that of amorphous salt (control I) indicated that furosemide-OSA 
starch solid dispersion was more hydrophilic and should have higher aqueous solubility 
than that of amorphous salt. This point was already demonstrated by aqueous solubility 
results. (Detailed solubility results in 3.1). 
 
 
3.3.6 Physical stability test (XRPD) 
 
 Solid dispersion physical stability (XRPD spectrum) at ambient condition (i.e. 
25±5 °C, 25-55%RH) for 4 months and 40°C for 3 months was shown in Figure 3-19. 
Physical stability (XRPD spectrum) at 40°C/75% RH for 2.5months was shown in 
Figure 3-20. 
 
 Solid dispersion kept its amorphous form when sample was treated under ambient 
condition or 40°C. During 3 to 4 months storage time, no crystalline was detected by 
XRPD technique. But when the samples were treated under 40°C/75% RH for 2.5months, 
crystalline was detected in all three solid dispersions (XRPD spectrum was shown in 
Figure 3-20). These phenomena indicated that furosemide-OSA starch solid dispersions 
were stable to high temperature, but they are fragile to humidity. Amorphous furosemide 
in solid dispersions was easily recrystallized under high moisture condition. For better 
application of OSA starch in solid dispersion, it was critical to prevent high moisture 
environment; specific packaging may used for this purpose 
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Table 3-4. pH measurements of control I before and after water vapor sorp-
desorp treatment. 
 
Control I Value 
Weight loss% in desorption 0.70% 
pH before DVS 5.63±0.1 
pH after DVS 5.91±0.19 
 
 
 
 
 
 
Figure 3-18. DVS graph of solution solid dispersions. 
 
  
 68 
 
 
 
 
Figure 3-19. Physical stability of solid dispersion at ambient condition and 40 °C. 
 
  
‐200
300
800
1300
1800
0 10 20 30
Co
un
ts
2θ
Soln. SD 1:5
Ambient 4 month 
(25 ±5 °C, 25-55%RH)
‐200
300
800
1300
1800
0 10 20 30
Co
un
ts
2θ
Soln. SD 1:7
Ambient 4 month 
(25 ±5 °C, 25-55%RH)
‐200
300
800
1300
1800
0 10 20 30
Co
un
ts
2θ
Control I
40 °C, 2 weeks
‐200
300
800
1300
1800
0 10 20 30
Co
un
ts
2θ
Soln. SD 1:1
40 °C, 3 month
‐200
300
800
1300
1800
0 10 20 30
Co
un
ts
2θ
Soln. SD 1:2.3
40 °C, 3 month
‐200
300
800
1300
1800
‐5 5 15 25 35
Co
un
ts
2θ
Soln. SD 1:9
40 °C, 3 month
 69 
 
 
 
 
Figure 3-20. Physical stability (XRPD spectrum) of solution solid dispersion under  
40 °C/ 75% RH for 2.5 months. 
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3.3.7 Dissolution 
 
For formulation I, drug released completely in 20 min for all test samples in 
phosphate buffer (pH 5.8), but when drug released in gastric acid medium, the drug 
dissolution slowed down. Around 80% furosemide released from amorphous solid 
dispersion 1:9 at 60 min; while for the 2nd one, Lasix 20mg, it released 43% drug at 60 
min point. Drug dissolution in acidic environment was in the order of solid dispersion 1:9 
>Lasix 20 mg > Control I > solid dispersion 1:2.3 > solid dispersion 1:1. (Dissolution 
profile was shown in Figure 3-21). Because furosemide is an acidic compound:  it 
remained essentially unionized when it was in acidic environment which made it less 
soluble. In this case, salt form didn’t help. High amount of OSA starch can keep a 
supersaturation state of drug in water which increased drug dissolution.  However 
amorphous solid dispersion 1:2.3 and 1:1didn’t show a benefit for drug release which 
may be for two reasons. One was the non-disintegrating property of the tablet which was 
caused by the stickiness of starch 1500, the other was that the starch amount wasn’t 
enough to maintain supersaturation effectively. Based on the analysis, MCC was selected 
to replace starch 1500 as filler to prepare formulation II to test if drug can release fast 
from amorphous solid dispersion: soln. 1:1 and soln. 1:2.3.   
 
For formulation II, drug released completely in 25 min for all test samples in 
phosphate buffer (pH 5.8), which was similar to that of formulation I. While in SGF, 
furosemide release was faster from soln. 1:1 and 1:2.3 after using MCC as filler than 
those using starch1500 as filler. Data is shown in Table 3-5. The results proved the above 
premise: the less stickiness of MCC helped the solid dispersion tablet to disintegrate and 
then allowed faster drug release. Dissolution profile of formulation II was shown in 
Figure 3-22. Faster disintegration can assist drug release but it was less effective in 
maintaining supersaturation of the drug.   
 
 
3.4 Conclusion 
 
The natural based OSA starch can be used as solid dispersion carrier to prevent 
drug crystallization, thus maintain an improved solubility and dissolution profile. 
Humidity proof package material should be considered in OSA starch based solid 
dispersion dosage form storage to maintain the drug in an amorphous state. Sample 
preparation methods, drug loading and tablet formulations have significant effect on 
solubility and dissolution profile of solid dispersions; various techniques including 
XRPD, SEM, FTIR, MDSC, DVS were applied to elucidate the mechanism of solid 
dispersion.  
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Figure 3-21. Dissolution profile of formulation I in SGF (pH 1.2) and phosphate 
buffer (pH 5.8).  
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w); 
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w); 
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w); 
Control I was amorphous furosemide ammonia salt; Lasix 20 mg was commercial 
furosemide tablet, the strength was 20 mg/tablet.  
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Table 3-5. Comparison of %drug release in two formulations at 60 min point in 
SGF (pH 1.2). 
 
Item Soln. 1:9 Soln. 1:2.3 Soln. 1:1 Control I Lasix 20 mg
Formulation I 80 19.6 5.4 37 43 
Formulation II 80 57 13 2 43 
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Figure 3-22. Dissolution profile of formulation II in SGF (pH 1.2) and phosphate 
buffer (pH 5.8).  
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w); 
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w); 
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w); 
Control I was amorphous furosemide ammonia salt; Lasix 20 mg was commercial 
furosemide tablet, the strength was 20 mg/tablet.  
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CHAPTER 4.    PHASE SOLUBILITY OF FUROSEMIDE WITH HP-Β-CD AND 
SBE-Β-CD, PREPARATION AND CHARACTERIZATION OF SOLID 
DISPERSIONS OF FUROSEMIDE AND SBE-Β-CD 
 
 
The purpose of the present study was to characterize the phase solubility of 
furosemide with Hydropropyl-β-Cyclodextrin (HP-β-CD) and Sulfobutylether-β-
Cyclodextrin (SBE-β-CD); solid disperson of furosemide and SBE-β-CD prepared by 
kneading, spray drying and freeze drying methods. The measured aqueous solubility of 
furosemide was 96 µg/ml. The phase solubility of furosemide-HP-β-CD complex was 
increased from 1.3-4.1 fold respectively in the concentration of 10-100 mM HP-β-CD. 
The K 1:1 and CE of the complex was 81 M-1 and 0.01 respectively. While phase 
solubility of furosemide-SBE-β-CD complex was increased from 3.6-30.6 fold 
respectively in 10-100 mM of cyclodextrins. The K 1:1 and CE of the complexes was 269 
M-1 and 0.0318 respectively. The equilibrium solubility and drug loading of solid 
dispersions were 167.9 ± 3.04 µg/ml, 165.5± 7.02 µg/ml, 115.0 ± 4.04 µg/ml, 86.0 ± 
19.88 µg/ml and 12.9 ± 0.23%, 14.7± 0.33 %, 13.6 ± 0.14 %, 7.04 ± 0.72% respectively 
for spray drying, freeze drying, kneading method and physical mixture ( drug: SBE-β-CD 
1: 1 mol/mol). For drug to SBE-β-CD (1:2 mol/mol) for spray drying and freeze drying 
solid dispersions, the equilibrium solubility was 162.6±19.8 µg/ml and 163.0±5.87 µg/ml 
respectively; the drug loading were 8.1 ± 0.43 % and 7.5± 0.99 %.  FTIR, SEM and DSC 
further verified the complex formation. XRPD showed that drug was in amorphous form 
in spray dried sample, while in other samples, drug was crystalline. The intrinsic 
dissolution data demonstrated that in SGF, the drug release was in the rank of SD > KD > 
FD > PM, while in the phosphate buffer (pH 5.8), the drug release was in the order of KD 
> PM > FD > SD. Solid dispersion tablet dissolution showed in acidic medium, drug 
release was in the order of SD > FD > KD >PM > commercial tablets, While in 
phosphate buffer (pH 5.8), drug released completely in 15 min for all samples. 
 
 
4.1 Introduction 
 
Cyclodextrin is cyclic oligomer of glucose which was extracted and separated 
from starch. It was widely used as drug solubilizer to enhance the aqueous solubility of 
poor water soluble drugs. The shape of cyclodextrin is like a double layer cylinder. The 
outside layer is hydrophilic which forms hydrogen bonds with water molecules, the 
inside cavity is hydrophobic which interacts with hydrophobic molecules or hydrophobic 
moiety of compound [114]. The molecular complex formation is the major mechanism 
for cyclodextrin solubilization function. Commonly, α, β or -cyclodextrin are often used 
which include 6, 7 or 8 glucose units. Besides original cyclodextrin, modified 
cyclodextrins which include HP-β-CD and SBE-β-CD are also used in many commercial 
products. The administration route is various, such as oral, rectal, buccal, ophthalmic, 
intravenous and intramuscular [115].  Compared to the original cyclodextrins, the 
modified cyclodextrins have benefits, such as low toxicity, high water solubility and high 
solubilization capacity [116]. 
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Furosemide is a loop diuretic which acts on the kidney to remove excess water 
and electrolytes into urine, thus reducing the body fluid. Furosemide was used to treat 
hypertension, congestive heart failure and edema [117]. It has also been used as 
veterinary medicine to treat horse bleeding [118]. Current drug products include tablets, 
oral solution and i.v. solution. The published oral bioavailability (BA) of furosemide was 
various, from 60~70% [119], or around 50% [120], or in the range 37~51% [114, 121]. 
Its oral absorption was quick, peak serum concentration (Cmax) was between 60 ~ 90min 
[122]. A big intra-viability around 20~84% and inter- subjects viability around 20~61% 
of BA were reported, too [98]. Furosemide was a BCS class IV drug which was low 
solubility and low permeability [123]. Chungi et al. investigated the site-specific 
absorption of furosemide in GI tract in rat model:  the drug was administered to stomach 
and small intestine, the rapid absorption occurred when furosemide was administered to 
stomach [124]. Site-specific absorption was also studied in human, an oral immediate 
release (IR) tablet was compared to an Intelisite® capsule which controlled drug release 
at a specific site in GI tract. In the clinical study, the relative BA of Intelisite® capsule is 
71% to oral IR tablet when furesemide was released at proximal small intestine, and there 
is no absorption when drug release at colon [125]. Furosemide dissolution in the stomach 
and then rapidly absorbed from upper GI tract, dissolution and solubility in stomach is 
the rate limiting step for its oral absorption [115, 122, 123]. 
 
Furosemide is one of the few oral BCS class IV drug products. It is often selected 
as model drug to test new formulation techniques or as candidate for drug optimization 
since its low and various BA. Cyclodextrins including β-cyclodextrin (CD), dimethyl- β-
CD and random-methylated β-CD were investigated for use in furosemide formulations. 
The solubility of furosemide is increased 3, 137 and 75 fold for βCD, dimethyl- β-CD 
and random-methylated β-CD respectively when the concentration of cyclodextrin is 
300mM [126]. The mechanism of complexation of furosemide and HPBCD as well as 
SBEBCD are characterized using DSC, XRPD and NMR by Spamer et, al.: the 
characteristic melting combined a decomposition peak shifted to higher temperature 
range in DSC; the XRPD spectrums show that the degree of crystallinity is reduced; 
1HNMR and 2D-NMR (ROESY) prove that the furan ring and part of the aromatic ring 
are entrapped in the hydrophobic cavity of cyclodextrin [100]. Phase solubility, 
dissolution properties and permeability of furosemide and HP-β-CD complex were also 
studied [119, 127, 128]. 
 
Various techniques have been used in furosemide solid formulation to increase its 
aqueous solubility and dissolution rate, i.e. dendrimer complex [129], the solubility 
increases around 110% per mM dendrimer added at the buffer with pH 4 to 6. The 
furosemide concentration in dissolution media is around 8 µg/ml at 2 hour point and 15 
µg/ml at 12 hour point under pH1.2; while drug concentration is around 12 µg/ml at 2 
hour point and 18 µg/ml at 12 hour point when dissolution medium is pH5.8.  
 
Self emulsifier drug delivery system technique has also applied to furosemide 
formulations [130]: mixture of surfactant and oil is screened to form self-microemulsion 
core, then furosemide is loaded at 1-10%. Solubility of furosemide in SEDDS in 1 mM 
hydrochloric acid solution (0.5 ml SEDDS/250 ml) is increased to 5.31 mg/ml. Drug 
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dissolution results show that the fastest drug release is around 55% and 100% at 4 hour 
point in 900ml dissolution medium (pH 3.0 and pH 6.8). The amount of drug in 
dissolution medium is not mentioned in article. Furosemide permeability increases as 
well in SEDDS. 
 
 In addition to above techniques, solid dispersion is applied in many furosemide 
formulations. At 75 min, 80% drug released in dissolution medium (pH 5.5) from 2 mg 
thermal carbonization mesoporous silicon (TCPSi) microparticles with about 40% drug 
loading. Furosemide permeation has been increased 5 fold when drug was loading on 
TCPSi microparticles [116, 131]. In furosemide-crospovidone coprecipitating or 
cogrinding samples, drug is present in amorphous form. At 60 min, drug concentration in 
dissolution medium (SGF, pH1.2) reached 25 mg/L [12]. Makoto et al. investigated the 
spray dried furosemide-Eudragit RS100 and RL100 solid dispersion: drug was in 
amorphous form, the dissolution showed solid dispersion initial release completely in less 
than 1 hour, then over time until 24h, drug concentration in dissolution medium (pH6.8) 
decreased due to absorption effect of polymer resin. Solid dispersion with 25% drug 
loading keeps its amorphous form for 24 days under 45°C/75%RH [132]. Shin et al. used 
TPGS to make solid dispersions, and the drug was in the amorphous form. At around 
30% (w/w) drug loading, the released concentration of furosemide was 40 mg/L in SGF 
(pH 1.2) [12]. Another two hydrophilic polymers: HPMC E50 LV and urea were studied 
to make solid dispersion. At 1 hour, around 70% and 35% drug released from solid 
dispersions: API to HPMC E50 LV and urea were 1:2 and 1:5 respectively.  Dosage 
forms equal to 10 mg drug was tested in 900 ml SGF (pH 1.2) [133].   
 
Changing solubility and dissolution  via solid dispersion, other formulation 
techniques including control release from EVA and PEG400 matrix tablet [134], taste-
masking [135], multiple unit gastroretentive floating drug delivery systems [136], 
solubilization using  micellar solutions of ethylene oxide and styrene oxide diblock 
copolymers [137] were all applied to furosemide.   
 
In the present study, the author selected HPBCD and SBEBCD for phase 
solubility experiment, and then SBEBCD was further used as carrier to make furosemide-
SBEBCD solid dispersion by three methods. The phase solubility, solid dispersion of 
furosemide and SBEBCD including aqueous solubility, dissolution (solid dispersion and 
tablet), and fully characterization (XRPD, DSC, FTIR, DVS), physical stability etc. are 
presented first time. 
 
 
4.2 Material and Methods 
 
 
4.2.1 Material 
 
Furosemide (Micronized) was generously donated by TEVA-TECH (Petah Tiova, 
49131, Israel). Hydropropyl –β-cyclodextrin (HP-β-CD) was provided by Roquette 
America, Inc. Sulfobutylether- β-cyclodextrin (SBE-β-CD Captisol®) was bought from 
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Cydex Inc. (Lenexa, Kansas, USA). All other chemicals were reagent grade and used as 
received. 
 
 
4.2.2 Phase solubility, apparent stability constant, complex efficiency  
 
The phase solubility test was performed as Higuchi and Connors method [138]. 
Excess amount of drug was added into triplicate 20ml screw capped vials which 
contained 10ml various concentrations of HP-β-CD, SBE-β-CD solution and R.O. water 
(pH 5.9). The vials were vortexed for 30 seconds at 1000 rpm, and then put on a shaker, 
shaking at room temperature (25 ± 1 °C) for three days. At the end of each day, the 
sample suspension was filtered through a 0.45um membrane filter and then diluted to 
proper concentration for HPLC analysis. One way ANOVA was used to test time needed 
for reaching equilibrium solubility of each complex. The HPLC system was a Shimadzu 
LC10 AD together with a Nova-Pak®C18 column (Waters, 4 μm, 150 mm Χ 3.9 mm, 
i.d.) and Diode Array Detector (Model SPD-M 10A). The mobile phase was 10mM 
potassium phosphate monobasic and methanol (60/40, v/v), adjusted pH to 2.5 by 
phosphoric acid. The flow rate was 1 ml/min and the detective wavelength was 276 nm.  
 
The complexation constant (K 1:1) and complex efficiency (CE) were calculated 
according to the Equations 4-1, 4-2 and the slope from phase solubility diagram.   
 
                K 1:1= slope / S0 (1-slope)   (S0 was solubility in water)  (Eq. 4-1) 
 
                              CE= S0 · K 1:1 = slope / (1- slope)   (Eq. 4-2) 
 
 
4.2.3 Preparation of furosemide: SBE-β-CD solid dispersion 
 
 
4.2.3.1 Kneading (KD) 
 
A kneader (Model IKA Duplex HKD 06D, Germany) was used to prepare 
furosemide loaded SBE-β-CD (1:1 mol/mol) solid dispersion. The powder mixture of 
furosemide 20g and SBE-β-CD 130.6g was wetted by ethanol and water 85:15 (v/v) to 
form paste and then was kneaded for 35min. The paste was dried overnight at 60 °C and 
then ground into powder by using coffee grinder.  
 
 
4.2.3.2 Freeze dry (FD) 
 
Furosemide and SBE-β-CD 1g, 6.53g or 13.06g (1:1 and 1:2 mol/mol) were 
dissolved in acetone / water (1:1 v/v) separately, and then mixed the two solutions to 
obtain a clear sample solution. The sample solution was frozen before putting in a freeze 
dryer (Labconco 4.5 liter freeze drying system) and then solvent evaporated under 
vacuum to get dry powder. 
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4.2.3.3 Spray drying (SD) and physical mixture  
 
The sample solution was prepared as that in freeze dryer and then delivered to the 
nozzle (0.7mm i.d.) of a Buchi 190 mini spray dryer (Switzerland) at a flow rate 5 
ml/min. The inlet temperature was 70 °C and outlet temperature was 41-44 °C; the 
compression air flow was about 700 L/h and aspirator was 80% (33m3/h). Physical 
mixture of furosemide and SBE-β-CD (1:1 mol/mol) was well mixed by passing 60 mesh 
sieve at multiple times.  
 
 
4.2.4 Aqueous solubility of solid dispersion in water 
 
The solid dispersion aqueous solubility was measured as in the method in 2.2. 
Excess amount of solid dispersion powder was added to triplicate 20 ml screw capped 
vial which contains 10 ml R.O. water (pH 6.0). The vials were vortexed for 30 seconds at 
1000 rpm, and then put on a shaker, shaking at room temperature (25 ± 1°C) for three 
days. At the end of each day, the sample suspension was filtered through 0.45μm 
membrane filter and then diluted to proper concentration for HPLC analysis. 
 
 
4.2.5 Solid dispersion powder characterization 
 
Particle size distribution (PSD), surface area, true density and bulk density were 
measured for drug, SBE-β-CD, physical mixture and solid dispersions. A static laser 
scattering particle size analyzer (Saturn DigiSizer 5200, Micromeritics®) was used for 
PSD measurements. A furosemide saturated isopropyl alcohol solution was prepared to 
disperse sample powder. The experiments were performed in triplicate. The surface area 
was measured with Gemini surface area analyzer (Micromeritics®) and calculated 
according to BET theory by the instrument automatically. True densities were determined 
using a pycnometer (Micromeritics® AccuPyc 1330) at ambient temperature. The bulk 
densities were assessed using around 8ml sample powder in a 10 ml graduated cylinder. 
 
 
4.2.6 Shape and surface morphology 
 
The photomicrographs of Furosemide, SBE-β-CD, physical mixture and three 
solid dispersion powders were obtained by environmental scanning electron microscope 
(ESEM) with backscattered electrons detector (QUANTA FEG 200, FEI Company). 
Powders were mounted on a double faced adhesive carbon tape, low vacuum (50 and 80 
Pa) applied in the chamber allows us to observe the powders without further treatment. 
The voltage was 10kV, working distance was 10 to 8 mm, spot size was 3 and the 
magnification time was from 250X to 5000X. 
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4.2.7 Drug content in solid dispersion powder 
 
Exactly weighed amounts of solid dispersion powders triplicate in the molar ratio 
of 1:1 of furosemide to SBE-β-CD were dissolved in the mobile phase and then sonicated 
samples for 10 min. Then the drug content was determined by HPLC after dilute to 
appropriated concentration.     
 
 
4.2.8 Spectroscopic and thermal characteristics 
 
Fourier transform-infrared spectra were obtained on a FT-IR spectrometer (FT-IR 
Perkin Elmer 100 UTAR). The sample powder was measured directly and no additional 
preparation. X-ray powder diffraction (XRPD) was applied to study the solid state form 
of solid dispersions. Thermal characteristics of furosemide, SBE-β-CD, PM, and solid 
dispersions were obtained by a differential scanning calorimeter (DSC100, Texas 
Instrument, USA). The samples were placed in aluminum pans and were tested with the 
following parameters: equilibrated at 30°C, ramp temperature 10 °C/min up to 310 °C for 
SBE-β-CD, ramp temperature 5 °C / min up to 240 °C for furosemide and solid 
dispersions.   
 
 
4.2.9 Dissolution  
 
 
4.2.9.1 Intrinsic dissolution 
 
Intrinsic dissolution behavior of furosemide and SBE-β-CD binary system was 
conducted to see if process methods had influence on drug release. Solid dispersion 
powder which was equal to 5 mg or 20 mg furosemide for SGF (pH 1.2) or phosphate 
buffer (pH 5.8) was compressed into intrinsic dissolution disks (USP Wood apparatus) 
with surface area 0.5 cm2 using a Carver press (Carver Inc., IL, USA ). The compress 
force was 1.1 mTon, dwelling time was 3 seconds. The dissolution medium was 600 ml, 
paddle speed was set as 100rpm and other parameters and test method were same as 
2.6.1. 
 
 
4.2.9.2 Tablet dissolution 
 
Simulated gastric fluid (pH 1.2) and phosphate buffer (pH 5.8) were prepared for 
tablet dissolution test. The experiment was conducted at 37°C using USP II method with 
50rpm paddle stirring speed and the volume of medium was 900ml. Three solid 
dispersions and physical mixture equivalent to 20 mg furosemide plus 4.7% Ai-Di-Sol 
were compressed into tablets. Compress force was 1.1 mTon, dwelling time was 3 
seconds. The percentage drug release was monitored using an on-line UV-Fiber optic 
dissolution system (Dynamic Dissolution Monitor™ system, Woodbridge Scientific 
LLC, CT, USA). 
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4.2.10 Dynamic vapor sorption (DVS) 
 
The hygroscopicity of API, physical mixture and solid dispersions were analyzed 
using a DVS-intrinsic instrument (Surface Measurement System) at 25 °C over the 
humidity range 0% to 90% RH with nitrogen gas as the carrier gas.  Sample size of 
approximately 5 mg was used according to the moisture uptake properties of SBE-β-CD. 
The solid dispersion sample has same drug content. 
 
 
4.3 Results and Discussion 
 
 
4.3.1 Phase solubility analysis  
 
The phase-solubility diagrams (PSD) of furosemide with SBE-β-CD and HP-β-
CD in water were showed in Figure 4-1, with the corresponding complexation constant 
(Kc) and complex efficiency (CE) values calculated from each PSD (Table 4-1). The 
measured intrinsic solubility (S0) and aqueous solubility were shown in Table 4-2. The 
aqueous solubility increased linearly as the function of SBE-β-CD and HP-β-CD 
concentration and the PSD can be classified as the AL type.  Solubility of three day’s 
complex were measured and compared using one way ANOVA. Furosemide: HP-β-CD 
complex needed three days to reach equilibrium state at 100mM, but for other lower 
concentrations and SBE-β-CD, one day is enough to reach equilibrium solubility. Since 
in many cases, the intrinsic solubility (S0) estimated from PSD can be sensitive to errors, 
thus the CE become more frequently and convenient used for compare when selecting 
CD in formulation development.  
 
 
4.3.2 Aqueous solubility of solid dispersion in water 
 
From the phase solubility study, the SBE-β-CD showed better solubility 
enhancement effect. Thus, SBE-β-CD was selected as carrier in the preparation of 
furosemide-loaded solid dispersions. In the present study, spray drying, freeze dry and 
kneader methods were chosen for sample prepare. The API and SBE-β-CD ratio was 1:1 
and 1:2 (mol/mol) for spray drying and freeze drying, but for kneader method, only 1:1 
ratio was tested considering the large amount of SBE-β-CD consumed. The aqueous 
solubility was showed in Table 4-3. Freeze dry and spray drying methods gave better 
solubility enhancement effect on API, but with the increasing amount of SBE-β-CD in 
solid dispersion, the solubility didn’t increase more which may further verify that 
furosemide and SBE-β-CD formed 1:1 complex. 
 
 
4.3.3 Solid dispersion powder characterization 
 
The micromeritical characteristics, including particle size distribution (PSD), 
specific surface area, true density and bulk density of three methods prepared solid  
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Figure 4-1. Phase-solubility diagrams of furosemide.  
     Furosemide SBE-β-CD complex. 
     Furosemide HP-β-CD complex. 
 
 
 
Table 4-1. K 1:1 and CE of phase-solubility studies of furosemide with SBE-β-
CD and HP-β-CD. 
 
Excipient K 1:1 (M-1) CE 
SBE-β-CD 273 0.035
HP-β-CD 81 0.010
 
 
 
Table 4-2. Aqueous solubility of furosemide-CDs complex at 25 °C. 
 
SBE-β-CD 
conc. (mM) 
Solubility of furosemide 
at 25 °C (μg/ml) 
HP-β-CD 
conc. (mM) 
Solubility of furosemide 
at 25 °C (μg/ml) 
0 41.82 ± 0.8 0 41.82 ± 0.8 
10 138.5 ± 3.0 10 119.7 ± 2.0 
20 238.0 ± 5.8 20 150.4 ± 3.1 
30 352.8 ± 10.3 30 175.3 ± 1.0 
40 462.9 ± 10.0 40 201.8 ± 3.1 
50 576.9 ± 31.6 50 228.5 ± 7.4 
100 1137.6 ± 6.0 100 396.5 ± 2.8 
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Table 4-3. Solubility of furosemide in solid dispersion prepared with three 
methods and the ratios of total solubility to the intrinsic solubility (n=3).   
 
Preparation 
method 
API: SBE-β-CD
(mol:mol) 
Solubility 
(µg/ml) 
Complex solubility/ 
intrinsic solubility 
(S/S0) 
Kneader 1:1 115.02 ± 4.04 2.74 
Freeze dry 1:1 165.50± 7.02 3.94 1:2 163.01± 5.87 3.88 
Spray dry 1:1 167.85 ± 3.04 4.01 1:2 173.9 ± 3.57 4.15 
Physical 
mixture 1:1 96.9 ± 5.71 2.31 
 
 
dispersion powder were shown in Table 4-4. The PSD was in the order of PM > kneader 
> FD > SD, the solid dispersion prepared using spray drying method gave smallest 
particle size, thus the biggest specific surface area and least dense powders. The kneader 
method gave bigger PSD, smaller specific surface area and dentist powders among the 
three methods.  
  
 
4.3.4 Shape and surface morphology 
 
SEM images of furosemide, SBE-β-CD, three solid dispersion powders and 
physical mixture were shown in Figure 4-2. Pure micronized furosemide was crystalline 
powder, with long irregular cylinder shape; the SBE-β-CD was in spherical shape 
suggested it was prepared by spray drying and the particle size was identical with results 
shown in Table 4-4.  
 
The SEM image of physical mixture pictured the fine micronized crystalline 
furosemide coated on the surface of SBE-β-CD.  
 
For the solid dispersion powders, KD powders have larger particle size than that 
of SD and FD samples. The particles have holes; in these holes furosemide crystals were 
highlighted and the crystalline distribution was not average. On fractures of the particles, 
crystals are rare; but on certain surfaces of these fine particles, the furosemide crystals 
were assembled in aggregates.  
 
For the FD powder, fine furosemide crystals were assembled in aggregates. While 
in other big blocks which showed a smooth surface on picture, it was hard to distinguish 
furosemide from cyclodextrin matrix. 
 
The spray dried solid dispersion was really small, to a large majority, much 
smaller than 5 μm which was identical with PSD measurements. It’s difficult to see in 
these powders the crystals of furosemide. At a magnification of 10000X, we find a few 
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Table 4-4. Particle size, specific surface area, true density and bulk density of 
solid dispersions, furosemide, and SBE-β-CD. 
 
Samples 
Particle size 
 (Median ± SD, 
μm)* 
Specific 
surface area 
m2/g 
True 
density 
(g/cm3) 
Bulk density 
(g/cm3)* 
Furosemide 5.04 ± 0.19 3.3294 0.8293 0.2636 ± 0.00056 
SBE-β-CD 1293.67±79.3 0.0864 0.6603 0.5400 ± 0.0018 
Kneader^ 90.44±2.72 0.4176 0.7344 0.6087 ± 0.0234 
Freeze dry^ 46.19±0.932 0.684 0.7759 0.5999 ± 0.01292 
Spray dry^ 7.125±0.621 1.3071 0.7814 0.3117 ± 0.01161 
Physical 
miscure^ 123.82±2.54 0.3894 0.6861 0.5494 
* n=3 for Particle size and bulk density. 
^API to SBE- β-CD ratio is 1:1. 
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Figure 4-2. Scanning electron micrographs of furosemide, SBE- β-CD, and 
furosemide SBE-β-CD 1:1 sodid dispersion prepared by different methods. 
(A)furosemide (5000×), (B) SBE-β-CD (250×), (C) solid dispersion prepared by the 
kneader method (1000 ×), (D) solid dispersion prepared by the freeze drying method 
(1000×), (E) solid dispersion prepared by the spray drying method (5000×), (F) physical 
mixture (250×). All solid dispersions were composed of furosemide : SBE-β-CD 1:1 
(mol:mol). 
 85 
but they are discreet. Much of furosemide adhered to the periphery of the spray dried 
spheres of SBE-β-CD but a fraction remained free which was clear displayed in physical 
mixture powders.  
 
 
4.3.5 Drug content in solid dispersion powders 
 
The drug content in each solid dispersion sample was shown in Table 4-5. The 
ratio between furosemide and SBE-β-CD was 1:1(mol:mol). The results accorded with 
the theoretical content: 13.3% except in the physical mixture sample. The less drug 
content in physical mixture was caused by API loss in sieve mixing process: the 
hydrophobic API adhered on the metal screen and didn’t dilute out by SBE- β-CD.  
 
 
4.3.6 Spectroscopic and thermal characteristics 
 
FTIR spectra of furosemide, SBE-β-CD and solid dispersions were presented in 
Figure 4-3. The characteristic absorption bands of furosemide at 1670 cm-1 was C=O 
stretching vibration of carboxylic acid group, 1591 cm-1 and 1561 cm-1 were N-H 
bending , the S=O stretching of the sulfonamide group was at 1318 cm-1 (asymmetric) 
and 1140 cm-1 (symmetric) [108]. The IR spectrum of physical mixture was similar with 
that of furosemide. In solid dispersios, the bands at 3399 cm-1, 3350 cm-1 and 3282 cm-1 
which were N-H stretching became wide and weak which was caused by bands overlap 
of SBE-β-CD or amorphous furosemide. The S=O stretching at 1140 cm-1 was shifted to 
1153 cm-1 and 1670 cm-1 C=O stretching of carboxylic acid group shifted to 1175 cm-1 
in spray dried sample indicated amorphous form of furosemide existed [117]. For KD and 
FD samples, the IR spectrum didn’t change much compared to that of PM, API 
maintained its crystal form in these samples which was also in agreement with the results 
of XRPD (Figure 4-4). 
  
The X-ray powder diffraction (XRPD) pattern of furosemide showed intense and 
sharp peaks in the spectrum proved it was crystalline [117]. The SBE-β-CD was 
amorphous without peak shown on XRPD. Samples prepared by kneading and freeze 
drying showed sharp peaks in the spectrum, but the intensity was not as high as that of 
API; the peaks indicated the crystalline form in the sample, since the drug content was 
around 13% in the two samples, the intensity of peaks was lower that of pure API. No 
distinguished peak shown in the spectrum of spray dried sample, the solid dispersion 
prepared by spray drying was predominantly amorphous form. A small crystal peak 
shown in the spectrum of physical mixture which indicated crystalline was here; and 
 
 
Table 4-5. Drug content of solid dispersion samples. 
 
API:CD=1:1 (mol:mol) KD FD SD PM 
Drug content % 14.7 ± 0.33 13.6 ± 0.15 12.9 ± 0.21 7.1 ± 0.17
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Figure 4-3. FTIR spectra of (A) furosemide (B) SBE-β-CD  (C) KD solid 
dispersion (D) FD solid dispersion (E) SD solid dispersion and (F) physical mixture. 
 
 
  
 87 
 
 
 
Figure 4-4. XRPD spectrums of furosemide, SBE-β-CD, furosemide solid 
dispersions prepared with kneader, freeze drying and spray drying method and 
physical mixture. 
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low drug content (7%) didn’t incur sharp diffraction peaks. From the XRPD spectrum, 
the crystalline degree was in the order of API (crystal) > Kneading ≈Freeze drying > 
physical mixture > spray drying > SBE-β-CD (amorphous). 
The DSC spectrum was shown in Figure 4-5. In the temperature range 207~219 
°C, a sharp exothermic peak was the characteristic melting combined decomposition peak 
of furosemide.14 In kneading (KD), freeze drying (FD) and spray drying (SD) solid 
dispersion samples, this sharp peak disappeared and decomposition phenomena was 
postponed to higher temperature range: 223~230 °C. No clear melting can be assigned to 
these spectrums. Actually, the author also tried the heat-cool-heat cycle and various 
heating rate (20°C, 40°C and 100°C /min) method to separate melting and decomposition 
events, but based on in house condition, no clear melting point was observed. For 
physical mixture (PM), the DSC was similar with that of other samples. All spectrums 
showed complex formed even in simple mixture.     
.  
 
4.3.7 Dissolution 
 
 
4.3.7.1 Intrinsic dissolution 
 
The intrinsic dissolution data (showed in Figure 4-6a and b) demonstrated that in 
SGF, the drug release was in the rank of  SD > KD > FD > PM, while in the phosphate 
buffer (pH 5.8), the drug release was in the order of KD > PM > FD > SD. In acidic 
environment, the drug solubility was the limit factor for dissolution. The fastest drug 
release sample was amorphous spray dried sample.  After compaction, small particles 
(more porosity) always form tighter compact and water penetration is slower than that of 
big particles. For similar crystalline samples, the dissolution rate of KD was faster than 
that of FD sample. In the phosphate buffer, dissolution rate was decided more by how 
fast the water penetrated into compact. Drug released faster from the loose compact KD 
and PM, but for SD and KD samples, a thin hydration layer formed on the surface of SD 
and FD sample which occluded continuing fast water penetration and made drug release 
slower after initial fast dissolution. 
 
 
4.3.7.2 Tablet dissolution 
 
After incorporating about 5% disintegrant, solid dispersion powders were 
compressed into tablets. In acidic medium, drug release was in the order of SD > FD > 
KD >PM > commercial tablets. This sequence was in accord with the solubility sequence. 
An abnormal phenomenon was observed that the spray dried and freeze dried tablet did 
not disintegrate which may caused by tight intra-particles physical binding. When drug 
released in phosphate buffer (pH 5.8), when solubility was not the limit factor, drug 
release finished in 15 mins for all samples. In this case, commercial product gave fastest 
drug release due to its perfect drug disintegration performance: disintegrated completely 
in 30 seconds (data is shown in Figure 4-7a and b). 
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Figure 4-5. DSC spectrum of SBE-β-CD, solid dispersions and furosemide.  
The ratio of furosemide to SBE-β-CD was 1:1 mol/mol.  
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Figure 4-6. Solid dispersion intrinsic dissolution profile. 
(a) Solid dispersion intrinsic dissolution in SGF (pH 1.2); (b) Solid dispersion intrinsic 
dissolution in phosphate buffer (pH 5.8). 
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Figure 4-7. Solid dispersion tablet dissolution profile. 
(a) Tablet dissolution in SGF (pH 1.2); (b) Tablet dissolution in phosphate buffer (pH 
5.8). 
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4.3.8 DVS 
 
Dynamic vapor sorption and desorption results were shown in Figure 4-8. The 
lower line with triangle marker was sorption curve and the upper line with square marker 
was desorption curve. Except for furosemide, the hydroscopicity of other samples was 
similar. The Low %RH values resulted in low vapor sorption and the water was only 
adsorbed on the sample surface. At 20% RH, the weight gain was in the order of SD 
(4.4%) >FD (3.1%)>KD (2.9%) >PM (2.0%) > SBE-β-CD (1.6%) >API (0.028%). This 
order was highly in accordance to the surface area of samples: the higher surface area, 
thehigh water uptake. In the case of API, the lowest water uptake was determined by its 
high hydrophobic properties. With increased RH, the sorption kinetics changed from 
dominated by surface adsorption processes to bulk absorption. At 80% RH, the water 
uptake order was SBE-β-CD (35.3%) > SD (33.7%) > PM (32.5%) >KD (30.8%) >FD 
(29.6%) >API (0.1%). This bulk absorption was related to the amorphous property of  
samples which was indicated by SEM picture and XRPD spectrum as well. The high 
vapor sorption of SBE-β-CD and SD sample are fully amorphous form. 
 
 
4.4 Conclusion 
 
The phase solubility of furosemide and SBE-β-CD and dissolution of its solid 
dispersions were first presented. The anionic ion SBE-β-CD in water at acidic pH can 
interact with hydrogen ions which benefited the drug solubility in acidic environment 
besides the function of parent cyclodextrin. In spray dried solid dispersion, the drug was 
armorphous whereas in kneading and freeze dried samples, drug was crystal. When 
powders were compressed into tablets, the tight physical bonding in spray dried and 
freeze dried samples made it hard to disintegrate even with 4.7% disintegrant. For further 
applying spray dry techniques to prepare solid dispersions for compressing tablets, a 
granulation step would be needed to get proper flow and to lower interparticle bonding 
for better tablet disintegration. The drug release of Lasix® was faster than those of others 
at phosphate buffer but slower in SGF. This because the disintegrant in the formulation 
play a critical role for drug release when solubility was not limit-factor, while in SGF, the 
disintegrant didn’t help drug solubilization. 
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Figure 4-8. Dynamic sorption and desorption diagram of furosemide, SBE-β-CD, 
solid dispersions and physical mixture. 
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